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Abstract
As an organ system, the lung has unique advantages and disadvantages for direct
drug delivery. Its contact with the external environment allows for the airways to be
easily accessible to intrapulmonary delivery. However, its complex structure, which
divides into more narrow airways with each branch, can make direct delivery to the
remote alveoli challenging. The objective of this thesis was to overcome this issue by
using exogenous surfactant, a lipoprotein complex used to treat neonatal respiratory
distress syndrome, as a carrier for pulmonary therapeutics. It was hypothesized that
therapeutics administered with a surfactant vehicle would display enhanced delivery
to the deeper regions of the lung. Acute respiratory distress syndrome and bacterial
pneumonia were selected as prototypical examples of pulmonary conditions in which
surfactant-drug combinations may be beneficial. Consequently, the pharmaceuticals
utilized were those with antibacterial or anti-inflammatory activities.
To test this hypothesis, the wet bridge transfer system was developed in Chapter
2 as a novel in vitro screening tool for surfactant-based therapeutics. Several antibiotic
and anti-inflammatory medications combined with a commercially available exogenous
surfactant were screened based on 1) surfactant spreading and 2) the biological efficacy
of the transported drug at a remote site. In Chapter 3 this platform, in combination with
other in vitro techniques, were utilized to gain the mechanistic insight required for
optimizing surfactant vehicle prior to animal studies. Specifically, through these
experiments a synthetic surfactant was designed, such that, the antibacterial activity of
cathelicidins, a family of potent antimicrobial peptides, was retained when transported to
a remote site. Finally, Chapter 4 used a rat model of lung inflammation, to assess the
ii

efficacy of this delivery approach for a mainstay anti-inflammatory. Surfactant based
delivery was found to downregulate of a wide variety of inflammatory markers across
both sexes.
To conclude, surfactant-based delivery of antimicrobial and anti-inflammatory
therapeutics was found to enhance drug delivery and efficacy at remote sites in vitro as
well as in vivo. Based on these findings, it is also suggested that future research expand
on the optimization process of this thesis for other surfactant-drug preparations and assess
those combinations in clinically relevant animal models.

Keywords
Exogenous pulmonary surfactant; synthetic surfactant; intrapulmonary drug delivery;
bacterial lung infection; acute respiratory distress syndrome; cathelicidins;
glucocorticoids; Pseudomonas aeruginosa.
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Summary for Lay Audience
The branching structure of the lung makes direct drug delivery to its more remote
regions challenging. The objective of this thesis was to overcome this delivery issue by
using exogenous surfactant as a carrier for drugs targeting the lung. It was hypothesized
that drugs administered with a surfactant would show enhanced delivery to the
more remote regions of the lung. Although many lung conditions could benefit from
this approach, this thesis focused on: acute respiratory distress syndrome (Lung
Inflammation) and bacterial pneumonia (Lung Infection). Consequently, the drugs
explored were those with the ability to kill bacteria and downregulate inflammation.
To test this hypothesis, the wet bridge transfer system was developed in Chapter
2 as a new screening tool for surfactant-drug mixtures. It was used to screen several
antibiotic and anti-inflammatory medications that were combined with an exogenous
surfactant, based on 1) surfactant spreading as well as 2) drug efficacy at a remote site. In
Chapter 3, this platform was combined with other techniques to design a better surfactant
vehicle for antibacterial peptides, known as cathelicidins. Finally, Chapter 4 used an
animal model of lung inflammation to assess the effectiveness an anti-inflammatory
medication delivered by a surfactant vehicle.
Together, the findings of this thesis support surfactant as a drug delivery vehicle
for anti-bacterial and anti-inflammatory medications. It is also recommended that future
research use the methods outlined in this thesis to design and evaluate surfactant vehicles
for other types of medication.
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Chapter 1: General Introduction and Literature Review

A version of this chapter has been published:
Baer B, Souza LMP, Pimentel AS, Veldhuizen RAW. (2019) New insights into
exogenous surfactant as a carrier of pulmonary therapeutics. Biochemical Pharmacology.
164: 64-73. doi: 10.1016/j.bcp.2019.03.036. Copyright Elsevier used with permission.
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1.1

General Overview

The therapeutic efficacy of any given drug is influenced by its ability to reach its
specific target cell, tissue, or organ. For some organs, such as the skin, accessibility is
relatively straightforward and topical drug administration can be highly effective with
limited side-effects. For other, internal organs, such as the liver or kidneys, drug
administration via systemic routes can be effective but can also be strongly affected by
drug metabolism and negative side-effects on other organs. Between these two extremes,
the lung presents itself as an organ system with distinct advantages and disadvantages for
drug delivery. Its direct contact with the external environment allows for potential
localized delivery; this, for example, allows for the highly efficient use of inhalers
(puffers) to administer bronchodilators and anti-inflammatory medications in asthmatics.
However, localized delivery becomes more difficult for therapeutics that are targeting the
deeper areas of the lung, in which the extensive branching structure and large surface area
provide substantial hurdles to adequate drug delivery. This problem gets exacerbated in
certain lung diseases in which edema fluid, lung collapse and/or tissue remodelling may
further affect accessibility.
The purpose of this thesis will be to investigate a potential solution to these latter
scenarios, namely the use of exogenous surfactant as a vehicle to improve the delivery of
pulmonary therapeutics. This first chapter will describe the complex branching anatomy
of the lung and features of exogenous surfactant that would make it ideal for enhancing
pulmonary drug delivery. It will also outline clinical scenarios, such as bacterial lung
infections and acute respiratory distress syndrome (ARDS), in which surfactant-based
therapeutics are deemed to have a strong clinical potential. Specifically, we will explore
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the mechanism of action and therapeutic potential of cathelicidins for bacterial lung
infections and glucocorticoids for ARDS.

1.2

Lung Structure and Function

The lungs are an essential component of the respiratory system, responsible for
facilitating gas exchange between the external environment and the bloodstream.
Specifically, oxygen and carbon dioxide are exchanged at the alveoli, moving across the
respiratory membrane. These molecules move down their concentration gradients,
resulting in oxygen diffusing across the epithelia and endothelia into the deoxygenated
blood within the surrounding alveolar capillaries [1, 2]. Carbon dioxide moves in the
opposite direction from the blood stream into the alveoli and is eventually exhaled out of
the body [1].
Located within the thoracic cavity, the lungs are enclosed by the rib cage and
diaphragm. The organ begins as the nasopharynx extends into the trachea, which in turn
divides into two main bronchi [1, 2]. Figure 1.1A illustrates this complex branching
structure of the airways, which continues to divide from the two main bronchi into
smaller and smaller sections, eventually forming the terminal bronchioles [1, 2]. From the
trachea to the terminal bronchioles, is referred to as the conducting zone [1, 2]. The
structures within this region are involved in air flow, but do not participate in gas
exchange. Beyond the terminal bronchioles are the respiratory bronchioles, that diverge
structurally from their terminal counterparts with the appearance of alveolar sacs [1, 2].
This division begins the respiratory zone, which refers to structures involved in gas
exchange [1, 2]. The alveolar sacs are clusters or groupings of multiple alveoli, each
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being surrounded by a dense network of capillaries [1, 2]. The unique branching structure
of the airways provides the lungs with a massive surface area at the level of the alveoli
and therefore facilitates rapid gas exchange [1, 2].
As illustrated in Figure 1.1B, there are two main cell types that cover the alveolar
surface, appropriately named alveolar type I and type II cells. The flat alveolar type I cells
cover the majority of the alveolar epithelium and facilitate gas exchange [3]. Their large
surface area and thin structure allow for the efficient diffusion of gas molecules during
normal respiration [3]. In contrast, the small number of type II alveolar cells cover a
much smaller portion of the alveolar surface. These cuboidal type II cells contain lamellar
bodies and are responsible for the production and secretion of pulmonary surfactant [3–
5]. A complex mixture of specialized surfactant proteins and lipids, pulmonary surfactant
is essential for normal breathing mechanics [4, 5]. Type II alveolar cells are also
responsible for replacing dysfunctional or damaged type I cells as well as contributing to
the innate immune defense of the alveolus [3]. Moreover, the alveolus also contains
resident macrophages that contribute to surfactant metabolism and immune defense,
through the engulfment of inhaled particles and pathogens [3].

5

Figure 1.1. Schematic representation of A) the branching anatomy of the airways and B) the alveolar space.

6

1.2.1 Pulmonary ventilation
To promote gas exchange, air needs to be moved in and out of the lung efficiently.
This is accomplished by changing the volume of the thoracic cavity, through a process
known as ventilation. Specifically, the volume is increased and decreased through the
contraction and relaxation of various respiratory muscles, including the diaphragm and
external intercostal muscles. As explained by Boyle’s law, increasing or decreasing the
volume of a closed container, in this case the thoracic cavity, will change its pressure
gradient with the external atmosphere [2]. Inspiration, or the movement of air into the
lung occurs through to the coordinated contraction of the diaphragm and external
intercostal muscles. These contractions expand the volume of the thoracic cavity such that
the air pressure within the lung is lowered below the air pressure of the external
environment. At rest, the relaxation of the diaphragm and external intercostal muscles is
enough to cause the lung to recoil to its original size, promoting expiration or the
movement of air out of the lung. During exercise, the increased rate of exhalation requires
the contraction of additional muscles, such as the internal intercostals, oblique and
abdominal muscles [2]. These additional contractions further decrease the volume of the
thoracic cavity, creating a larger pressure gradient with the external environment and
forcing more air out of the lung.
In addition to the contraction and relaxation of respiratory muscles, ventilation is
also affected by distensibility [2]. This property, known as lung compliance, refers to the
volume to which the lungs expand per unit of air pressure change [2]. Thus, a lung with
low compliance requires a greater amount of force or work from the breathing muscles to
inflate. There are two major characteristics of the lung that impact lung compliance: 1)
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the elastic properties of the lung tissue and 2) the surface tension within the alveoli [2].
The elasticity of the lung tissue is based on the flexibility of its structural components.
Specifically, the amount of collagen or elastin fibers that are meshed inside the airway
interstitium regulate this aspect of lung compliance [2]. For example, the more collagen
the greater the elastic resistance of the lung and therefore the greater the force required to
cause the lung to expand. Surface tension within the lung is created at the air–liquid
interface by the attractive force between water molecules, in the fluid lining the airways.
These water molecules pull towards each other, in an attempt to force air out of the
alveoli, creating a resistance force to the expansion of the region [2]. As such, a high
surface tension at the alveolar surface results in a low lung compliance. It is the role of
pulmonary surfactant secreted into this fluid layer to reduce surface tension at the air–
liquid interface (Figure 1.1B) [2, 4, 5]. The surface tension lowering properties of
surfactant are essential for normal lung function and influence both lung compliance as
well as alveolar stability [4, 5].

1.2.2 The pulmonary surfactant system
As mentioned above, pulmonary surfactant is a lipoprotein mixture produced by
the alveolar type II cells [4, 5]. The mixture is stored inside of these alveolar cells in
structures known as lamellar bodies, until it is secreted into the fluid lining the airways
[4–6]. Pulmonary surfactant then adsorbs through this fluid layer to the air–liquid
interface. During respiration, the surfactant film reduces surface tension based on its
concentration at this interface [4, 5]. During exhalation, the surfactant film is compressed
or becomes more concentrated at the air–liquid interface, allowing the alveolus to achieve
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very low surface tensions (near 0mN/m). However, when the film is expanded or
becomes less concentrated during inspiration, surfactant reduces surface tension in the
alveolus to a lesser degree (5-30mN/m) [4, 5]. By reducing surface tension, pulmonary
surfactant promotes normal lung compliance and prevents alveolar collapse during
exhalation [4, 5]. The functional components of pulmonary surfactant, that produce the
surface tension lowering film are collectively known as “large aggregates”. As the surface
film is compressed and expanded, the process also creates small vesicles of surfactant,
which will be either taken up by alveolar type II cells for recycling or alveolar
macrophages for degradation [7]. These vesicles are the inactive components of surfactant
and are collectively referred to as “small aggregates”.
Pulmonary surfactant can be isolated from lung lavage material by differential
centrifugation and the analysis of surfactant from numerous mammalian species has
revealed a well conserved composition [8, 9]. Approximately 85% of the surfactant
consists of phospholipids. Phosphatidylcholine (PC) being the most abundant at ~75% of
the total phospholipid fraction, with more than half this phospholipid being represented
by the saturated species dipalmitoylphosphatidylcholine (DPPC). Phosphatidylglycerol
(PG) is the second most abundant phospholipid at ~10%, with other phospholipids, such
as sphingomyelin and phosphatidylethanolamine, present in lower amounts [4, 8]. In
addition to phospholipids, surfactant also contains ~5-8% neutral lipids, predominantly
cholesterol, as well as 7-10% surfactant associated proteins designated SP-A, SP-B and
SP-C [8, 10]. Of note, a fourth protein, SP-D, has also been identified but is not coisolated with the surfactant obtained by centrifugation [11]. The surfactant proteins B and
C, are small hydrophobic proteins that are tightly associated with the lipid fraction of
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surfactant [12, 13]. SP-A and SP-D are also large multimeric glycoproteins of the
collectin family [14, 15].
The function of pulmonary surfactant can be broadly divided into two parts, its
biophysical function [4, 16, 17] and its host defense function [18, 19]. This thesis will
focus on the biophysical properties of pulmonary surfactant, however its role in host
defense has been reviewed elsewhere and appears to be mainly mediated through SP-A
and SP-D [14, 18, 20]. The biophysical role of surfactant consists of forming a surface
tension reducing lipid film at the air–liquid interface of the alveolar surface, with further
reduction of this surface tension to near zero mN/m during exhalation when the film is
compressed as the surface area of the lung decreases [4, 16, 21]. This reduction of surface
tension stabilizes the lung (i.e. it prevents alveolar collapse) and allows for inflation with
relative ease.

1.2.3 Biophysical functions of pulmonary surfactant
The biophysical properties of pulmonary surfactant are mediated through its
phospholipid components and specialized proteins [4, 16, 21–23]. Specifically, DPPC is
thought to be mainly responsible for the surface tension lowering properties of pulmonary
surfactant, while the other lipids and surfactant proteins play a role in the formation and
maintenance of the surfactant film [4, 16, 21–23]. Briefly, to accomplish its biophysical
functions, pulmonary surfactant must have enough fluidity to rapidly transfer its surfaceactive molecules to the air–liquid interface, and film stability, such that, it can tightly
pack its components at the surface during compression.
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Experimentally, the rapid adsorption (i.e. transfer of surface-active components to
the air–liquid interface) and surface tension lowering properties of pulmonary surfactants
have been demonstrated in numerous experiments [8, 16]. Often performed using a
Langmuir probe to measure surface tension, these experiments have found that functional
surfactants can significantly reduce surface tension to equilibrium values (approx. 23
mN/m) [8, 16]. Mechanistically, the surface tension reducing properties of pulmonary
surfactant have been shown to be mediated by its phospholipids (most importantly
DPPC), which displace water molecules at the air–liquid interface [4, 8, 16, 22, 24, 25].
By occupying this interface, these amphipathic phospholipids seem to displace water
molecules and therefore reduce their collapse or pull force away from air. Although
monolayer experiments have also shown that liposomes of pure DPPC can reduce surface
tension to equilibrium values, these liposomes adsorb very slowly relative to natural or
lipid extract surfactants [24, 25]. These findings suggest that other surfactant components
are required for the rapid formation of a surfactant film. Notably, SP-B and SP-C have
been shown to enhance the adsorption and spreading capabilities of lipid mixtures,
including pure DPPC, in vitro [26–28]. Further, experiments utilizing radioactively
labelled surfactant lipids have demonstrated the ability of SP-B and SP-C to break stable
phospholipid bilayers and promote the insertion of lipids into a surface film [28].
Additionally, other Langmuir-Wilhelmy studies have found that the level of non-DPPC
surfactant lipids, including PG, unsaturated PC, and cholesterol, can also affect the ability
of pulmonary surfactant to adsorb and spread, presumably by affecting film fluidity [29,
30]. Thus, the rapid adsorption of pulmonary surfactant to equilibrium seems to require
both DPPC, as well as various other lipids, and specialized proteins.
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The ability of pulmonary surfactants to reduce surface tension to even lower
values (near 0mN/m) during compression has been illustrated by experiments utilizing the
pulsating, captive, and constrained sessile drop surfactometers (CDS) [16, 31, 32]. This
further reduction in surface tension during exhalation is thought to be linked to the
surfactant film being reorganized when compressed, such that, it is enriched in the
saturated phospholipid DPPC [4, 16, 21–23]. Basically, interfacial compression is
theorized to cause the “squeeze out” of the more fluid, unsaturated lipids within surfactant
from the interface, leaving the more solid DPPC. Experimentally, this DPPC refinement
has been shown to be mediated through SP-B and SP-C, allowing the surfactant film to
achieve very low surface tensions because DPPC can be tightly packed without
collapsing, presumably due to its desaturated acyl chains [29, 33]. Mass spectrometry has
also been used to show the creation of separate DPPC and non-DPPC lipid monolayers
during surfactant compression [21]. Briefly, the study demonstrated that unsaturated
phospholipids were “squeezed out” of the surfactant film, leaving a monolayer enriched
in desaturated phospholipid species [21]. Together, these studies highlight the role of
surfactant proteins, in addition to DPPC, for the surface tension lowering properties of
pulmonary surfactant during compression.

1.2.4 Exogenous surfactant therapy
The origins of exogenous surfactant therapy lie in the discovery of endogenous
surfactant and the clinical finding of surfactant deficiency in preterm infants, a story
chronicled in several excellent reviews [34–38]. Briefly, the critical importance of
endogenous surfactant for normal lung function is obvious from the severe lung
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dysfunction observed in preterm infants with surfactant deficiency [35, 38]. This
condition, termed neonatal respiratory distress syndrome (NRDS), was a major cause of
infant mortality until the mid-1980’s at which time clinical trials showed the efficacy of
exogenous surfactant therapy [38, 39]. Intratracheal administration of a purified version
of animal surfactants was found to significantly increase survival in this vulnerable
patient population [40–43]. As such, exogenous surfactant is currently standard therapy in
neonatal intensive care units (ICU) [44].
The success of exogenous surfactant in NRDS prompted investigations of this
therapy in other lung conditions, most notably ARDS [45, 46]. ARDS can be caused by a
variety of initiating insults and is defined by severe lung dysfunction [47–49]. This
physiological impairment of lung function showed similarities with observations in
NRDS. However, whereas NRDS can be diagnosed immediately at the onset of the injury
and is due to surfactant deficiency [35, 38], ARDS is diagnosed later in the disease
process when injury is well-established and is associated with surfactant impairments [17,
50, 51]. Nevertheless, the similarities prompted extensive research into exogenous
surfactant therapy for this disease [52–55]. Unfortunately, the initial clinical trials and
subsequent meta-analysis of the data did not indicate an improvement in mortality due to
surfactant therapy in ARDS [46, 56–61]. Specifically, these clinical trials found that the
benefits of surfactant therapy for ARDS patients were largely limited to improvements in
blood oxygenation. However, as stated in a recent review by Veldhuizen et al., the
emergence of severe acute respiratory syndrome coronavirus 2 (COVID-19) related
ARDS has prompted a reconsideration of this clinical approach [62]. Specifically,
researchers have begun to re-examine the negative results of these early trials with respect
to the dose, delivery method and timing of administration [62]. Moreover, the therapeutic
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role of exogenous surfactant in the treatment of ARDS has also been revaluated to include
(among other approaches), its potential as a drug delivery vehicle [62]. These new
insights into the potential role of exogenous surfactant for treating ARDS as well as the
limitations of previous trials, have led to five ongoing clinical trials of surfactant therapy
for COVID-19 patients [62].

1.2.4.1 Animal derived and synthetic exogenous surfactant preparations
Underlying the above information on the clinical utilization of exogenous
surfactants is, obviously, the extensive research and development to produce these
therapeutics. The general composition of a select number of currently available
preparations is shown in Table 1. The most frequently utilized surfactants are the animal
derived preparations obtained from lung lavage material from cattle or pigs [63, 64].
These exogenous surfactants undergo a lipid extraction with organic solvents and as such
contain the surfactant lipids as well as the two hydrophobic proteins (SP-B & SP-C). A
second type of animal derived exogenous surfactant can be created through the extraction
of minced lung tissue with supplementation of DPPC and palmitic acid to enhance the
spreadability of the material [65–67]. These preparations contain surfactant proteins B
and C, although in lower amounts compared to lavage derived surfactants. Additionally,
several synthetic surfactant preparations have also been produced. In general, these
synthetic surfactants contain DPPC, PG, and some other lipids, as well as components
that allow the lipids to spread [68–73]. In the most promising artificial surfactants, these
components are analogues of surfactant proteins B and/or C, such as Mini-B or the
synthetic peptoids [72, 73]. For example, CHF5633, a newly developed synthetic
surfactant, is enriched with SP-B as well as SP-C peptide analogues, and was found to
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have similar clinical efficacy for treating NRDS compared to an animal derived surfactant
[74]. Thus, the high efficacy of these synthetic analogues have made the most recent
artificial surfactants viable, low cost, and highly versatile alternatives to animal derived
surfactant replacements [72–74].
Regardless of the preparation method and specific composition, the functional
characteristics, as required for the treatment of NRDS, are similar. An exogenous
surfactant should be able to adsorb onto, and spread along, an air–liquid interface,
reflective of its ability to distribute throughout the lung when instilled as a bolus liquid.
During dynamic compression and expansion cycles these surfactants should be able to
reach low surface tension of below 5 mN/m, indicative of the ability to reduce the surface
tension at the alveolar wall during inhalation and exhalation to facilitate ventilation with
minimal effort.
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Table 1.1. Compositions of various exogenous surfactant preparations.
Lavage-derived surfactants

Minced lung surfactants

Synthetic surfactants

Surfactant
Component

Bovactant
Alveofact®

Calfactant
Infasurf®

BLES
Bles®

Poractant
alfa
Curosurf®

Beractant
Survanta®

Colfosceril
Exosurf®

Lusupultide
Venticute®

Lucinactant
Surfaxin®

CHF5633

DPPC

32%

31%

33%

37%

65%

100%

70%

75%

50%

Unsat PC

50%

45%

53%

37%

22%

0%

0%

0%

0%

PG

9%

6%

11%

1%

3%

0%

30%

25%

50%

Other
phospholipids

9%

18%

3%

25%

10%

0%

0%

0%

0%

Neutral
lipid

Cholesterol

Cholesterol

Cholesterol

FFA

Cholesterol
FFA

none

FFA

FFA

None

Surfactant
Proteins

SP-B
SP-C

SP-B
SP-C

SP-B
SP-C

SP-B
SP-C

SP-B
SP-C
Hexadecanol,
Tyloxapol

Recombinant
SP-C

KL4 peptide

SP-B and
SP-C
analogs

Synthetic
Additives

Phospholipids are expressed as reported averages as a percentage of total phospholipids. See text for references. DPPC:
dipalmitoyl phosphatidylcholine; Unsat PC: Unsaturated phosphatidylcholine; PG: phosphatidylglycerol; FFA: free fatty acids;
SP: surfactant protein. Other phospholipids within these surfactants may include phosphatidylserine,
phosphatidylethanolamine, phosphatidylinositol, and sphingomyelin.
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1.3

Exogenous Surfactant as a Drug Delivery Vehicle

The successful treatment of inflammatory or infection-based conditions of the lower
respiratory tract, require medications to achieve adequate therapeutic concentrations at
the alveoli. Unfortunately, this is made particularly difficult by the complex branching
structure of the airways (i.e. becoming more narrow with each division) as well as airway
collapse associated with these conditions [1, 75–78]. Despite this delivery issue, the
administration of therapeutics directly to sites of infection or inflammation within the
lung has numerous benefits over systemic dosing, including increased therapeutic
concentrations within the lung and reduced risk of systemic toxicity [79–81]. This
concept is best illustrated by the low toxicity and high therapeutic efficacy of aerosolized
glucocorticoids in the treatment of asthma [82–84]. Unfortunately, along with aerosolized
antibiotics, these inhaled medications tend to accumulate in the central airways, limiting
their ability to reach peripheral sites of infection or inflammation [76, 81, 83]. Thus, other
direct delivery methods need to be explored to enhance bioavailability at peripheral sites,
while limiting side effects [85, 86].
The overall concept of exogenous surfactant as a pulmonary drug delivery agent is
relatively straightforward and originates from the success of exogenous surfactant therapy
as utilized in conditions such as NRDS [40–44]. Briefly, intratracheally administered
exogenous surfactants can adsorb and spread at the air–liquid interface of the airways.
This allows exogenous surfactants to distribute throughout the lung, reaching and
reducing surface tension at the alveoli (see section 1.2.2 The pulmonary surfactant
system). Its ability to spread to the alveoli, when administered intratracheally, inspired the
idea that exogenous surfactants could also be utilized as delivery vehicles for pulmonary
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therapeutics and other compounds [62, 77, 87–89]. The basic premise is that when
combined, exogenous surfactant will facilitate the delivery of a compound to the remote
areas of the lung.
A few studies have tested this concept experimentally by directly evaluating
pulmonary drug distribution. For instance, studies have utilized fluorescently or
radioactively label therapeutics to evaluate the distribution of surfactant-drug mixtures in
vivo [89, 90]. One such study, utilized excised hamster lungs that were sliced into 3-mm
cross sections, to quantify the distribution of a radioactively labelled version of
pentamidine following intratracheal instillation with saline or an exogenous surfactant.
Utilizing an exogenous surfactant as a carrier for the radioactively labelled compound
resulted in radioactivity being detectable in more of the lung slices (93%) compared to
saline (72%) [89]. The radioactivity was also detectable over a larger fraction of the lung
slices analyzed, when the compound was instilled with surfactant (43%) compared to
saline (21%). The study concluded that exogenous surfactant not only resulted in a more
uniform distribution of the anti-infective agent, but that it also delivered the drug to a
greater portion of the lung [89]. A similar distribution study in rats, used a radioactively
labelled version of dexamethasone to quantify drug levels in both the lung and circulation
following administration via either intratracheal instillation or intravenous injection [91].
For intratracheal instillation, the use of an exogenous surfactant as a carrier for
dexamethasone resulted in significantly greater lobar delivery compared to saline, with
radioactivity being associated with the small airways and alveoli of the lung [91].
Together, this published data demonstrates the enhanced pulmonary distribution that
occurs for drugs delivered by a surfactant vehicle.
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Another characteristic of exogenous surfactant that supports its usage as a pulmonary
delivery vehicle, is its safety. The utilization of any therapeutic, including exogenous
surfactants, in a patient population requires controlled clinical trials to examine the
efficacy and safety of the therapy. Although some care needs to be taken with surfactant
preparations to avoid the formation of stable bubbles capable of blocking airways, no
major negative side effects have been reported for surfactant administration. This includes
not only the evidence from its utilization in NRDS [40–43], but also the data on safety
obtained in the various ARDS trials [46, 56–60]. The safety and toxicology of the
selected drugs to be utilized with surfactant would vary among all compounds. However,
the premise of surfactant-based drug administration is lung targeted delivery, which
would further limit potential side effects associated with systemic administration.
Despite its origins for treating NRDS, it should also be noted that the drug carrier
approach for exogenous surfactant targets a different clinical outcome than the simple
restoration of the surfactant system. As such, there are clear distinctions that need to be
considered for this approach. First, it is imperative that the therapeutic that is mixed with
the exogenous surfactant associates with the surfactant but does not inhibit its ability to
spread throughout the lung. It is also important that the exogenous surfactant’s ability to
reduce surface tension is maintained to open areas of the lungs that are collapsed. The
opening up of these collapsed lung units would allow these injured areas to become
accessible for the delivered drug. Conversely, it is similarly important that the function of
the drug being delivered to the lung is maintained in the presence of the exogenous
surfactant and that the drug reaches its intended target. The development of a new in vitro
technique that can screen surfactant-based therapeutics based on these characteristics is
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the basis for our wet bridge transfer system, described in Chapter 2. In addition, the
assessment of a surfactant-based therapeutic in vivo is the basis of Chapter 4.
Lastly, based on the additional variables associated with surfactant-drug
combinations, these compounds may require the use of newly designed synthetic
surfactants. For example, whereas animal derived surfactants are utilized extensively, and
successfully, for surfactant treatments for NRDS, these preparations have a defined lipidprotein composition (Table 1.1). Interaction of a potential therapeutic with surfactant can
be affected by that composition. As such, there may be scenarios in which synthetic
surfactants are more suitable for drug delivery purposes. In general, synthetic surfactants
are more amendable to altering the specific composition and could therefore be optimized
for surfactant-carrier interactions. This concept of designing a synthetic surfactant for a
specific therapeutic is explored in Chapter 3. Further, although each specific therapeuticsurfactant combination will require a targeted research approach, a general overview of
the process we explored throughout this thesis is outlined by Figure 1.2.
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Figure 1.2. Schematic summary of surfactant-based drug development.

1.4

Respiratory Conditions that Could Benefit from

Surfactant-based Therapeutics
Throughout this literature review, we have explored many preclinical studies that
highlighted the ability of exogenous surfactants to facilitate the distribution of
antibacterial and anti-inflammatory agents to remote regions within the lung. Moreover,
surfactant as a drug carrier has been used clinically, to treat preterm babies at risk for the
development of bronchopulmonary dysplasia (BPD) [92–95]. BPD is a chronic lung
disease which develops in premature infants, especially those exposed to prolonged
ventilation and high oxygen. In two controlled clinical trials, the effect of an exogenous
surfactant, Survanta, with budesonide was compared to surfactant alone with respect to its
efficacy in preventing the development of BPD in premature infants [92–94]. The data
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provided by the two clinical trials has been analyzed in a systematic review and metaanalysis which concluded that intra-tracheal administration of budesonide-surfactant
mixtures decreased the incidence of BPD [96, 97]. However, considering the limited
number of trials to date, both by the same team of investigators and with the same
surfactant preparation, both papers also indicated the need for additional large clinical
trials prior to recommending this approach as a standard therapy.
Whereas these clinical trials for BPD provide the first proof-of-principle for this
delivery approach in patients, the clinical utilization of a surfactant-drug combination in
other conditions is lagging. Notably, the expansion of promising preclinical data for
therapeutics delivered by a surfactant vehicle in the treatment of bacterial pneumonia and
ARDS.

1.4.1 Bacterial lung infections
Bacterial pneumonia is an infection of the lower respiratory tract and the leading
cause of death due to infection worldwide [98]. The World Health Organization estimates
that pneumonia accounts for approximately 15% of deaths under the age of 5, and 3.2
million deaths annually [98–101]. These statistics encompass a diverse range of
conditions including community-acquired pneumonia, ventilator associated pneumonia
(VAP), hospital-acquired pneumonia, cystic fibrosis, as well as pneumonia resulting from
complications of other diseases [98, 99, 102–105]. The current treatment paradigm for
bacterial lung infections involves the administration of high-dose oral or systemic
antibiotics [105–107], however, additional treatment strategies are required to overcome
current and future therapeutic challenges.
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The rationale for using exogenous surfactant-based therapies to treat this respiratory
condition was outlined, in general, in a previous section (see section 1.3 Exogenous
Surfactant as a Drug Delivery Vehicle) and includes the need for localized delivery in the
deeper areas of the lung [75]. Simply put, the clearance of a bacterial infection requires
adequate antibiotic concentrations at the site of infection. Consequently, the sublethal
pulmonary bioavailability from oral, systemic, or aerosolized medications may, in fact, be
partly responsible for another hurdle in the treatment of these infections, the increasing
incidence of antimicrobial resistance (AMR) [76, 81, 104, 108–111]. Moreover, the
problem of AMR is not limited to lung infections as it is considered one of the largest
current and future threats to global health in general [112–114]. Complicating treatment
further, chronic inflammation associated with lung infections also contributes to the
adverse outcomes in bacterial pneumonia [98, 106, 115, 116]. For example, in CF and
VAP patients, the bronchial mucus layer and endotracheal tube, respectively, can act as
reservoirs for bacteria [103, 106, 107, 117]. Consequently, these reservoirs can prevent
the host immune system from fully clearing the infection. This leads to a prolonged
bacterial colonization of the lungs, increased incidence of AMR, and excessive
inflammation that can damage the respiratory system [103, 106, 107, 117]. Therefore, the
treatment of bacterial lung infections, may require immunomodulatory therapeutics, in
addition to new antimicrobial agents.
Focusing on AMR infections in the lung, it is estimated that nearly 30% of clinical
pneumonia isolates from ICU or nursing home patients are resistant to three or more
antibiotics, with pathogens such as Pseudomonas aeruginosa (P. aeruginosa) being
particularly problematic [98, 118, 119]. Specifically, this gram-negative bacterium has
shown a higher capacity for acquiring resistance mechanisms against mainstay
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antibiotics, including biofilm development as well as increased expression of efflux
proteins and inactivating enzymes [119, 120]. Additionally, in pneumonia patients
susceptible to frequent, spontaneous, or chronic infections, their need for prolonged
antibiotic treatment promotes even higher rates of AMR [117, 121–125]. Notably, these
spontaneous infections are most commonly caused by P. aeruginosa or Staphylococcus
aureus (S. aureus), among other pathogens [98, 120]. In conditions such as CF, the
acquisition of AMR bacteria represents a pivotal stage in disease progression that is
linked with poor outcomes, due to the limited treatment options available [116, 126].
Despite this rising incidence of AMR, there are very few new antibiotics currently being
developed [98, 127–130]. This has pushed many researchers to explore new sources of
antimicrobial therapeutics, in addition to new routes of drug delivery [127].

1.4.1.1 Antimicrobial peptides: cathelicidins
Antimicrobial peptides are found in the innate immune system of almost all
classes of life [131–133]. Specifically, they represent a diverse group of more than 3000
distinct and endogenously produced peptides [131–133]. Due to their diversity,
classification can vary, however antimicrobial peptides are often subdivided based on
their source, activity, structural characteristics, and amino acid composition [131, 133]. In
general, antimicrobial peptides are relatively small (under 100 amino acids) and
positively charged [131, 133]. This thesis will focus on one of the main categories of
mammalian antimicrobial peptides, cathelicidins, which were utilized in our studies
(Table 1.2)[131].
Cathelicidins are a family of antimicrobial peptides present in the innate immune
defense systems of many vertebrates, including humans [134], pigs [135, 136], chickens,
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[137, 138], and mice [139] (among many others) [140]. Almost all epithelial or immune
cells contain a cathelicidin, with the highest concentrations being found in neutrophils
[140–142]. Within immune cells, the N-terminal sequence is responsible for the
movement of the inactive peptide into storage units known as secretory granules, at which
point the sequence is removed [140, 143, 144]. When immune cells interact with a
inflammatory marker, microbe, or pathogen that requires an immune response the
secretory vesicles are released [140, 143, 144]. Then a specific protease cleaves the
“cathelin” domain, allowing for the mature cathelicidin to elicit its antimicrobial and
immunomodulatory functions [140, 143, 144]. This family of peptides derives its name
from a 99 to 114 amino acid pro-sequence, referred to as the “cathelin” domain; a region
with close homology to cathelin (the cathepsin L inhibitor) [140]. This domain is highly
conserved across species, however it is only found in the inactive, pro-peptide [140]. The
full-length pro-peptide contains an N-terminal signalling sequence, the “cathelin”
domain, and a short antimicrobial domain at the C-terminus [140, 145]. The biologically
active cathelicidin will consist of this small (12 to 100 amino acids) C-terminal sequence,
which displays very high interspecies and intraspecies diversity [140, 144, 145].
Consequently, mature cathelicidins are quite diverse in their structure, net charge, amino
acid sequence length and/or composition, as well as antimicrobial or immunomodulatory
activity (Table 1.2) [140, 144–146].
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Table 1.2. Characteristics of cathelicidins explored in this thesis.

Peptide

Mature Amino Acid Sequence

Length

Charge

*Antimicrobial

+Anti-inflammatory

Activity

Activity

Structure

E. coli

S. aureus

LPS

LTA

CRAMP

ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE

38

+6

One α-helix

9 hrs

0.5 hrs

5 µM

20 µM

LL-37

LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

37

+6

One α-helix

10 µM

0.5 hrs

1.25 µM

0.31 µM

CATH-2

RFGRFLRKIRRFRPKVTITIQGSARF-NH2

26

+9

5 µM

2.5 µM

5 µM

1.25 µM

9.5 hrs

20 µM

>20 µM

20 µM

Two α-helices
connected by
a proline hinge
Two α-helices
PMAP-23

RIIDLLWRVRRPQKPKFVTVWVR

23

+6

connected by
a proline hinge

*Antimicrobial activity refers to the cathelicidin concentration (0.33-20 μM) that significantly delayed bacterial growth (1x106
CFU/ml) of E. coli or S. aureus for a minimum of 10 hours in Mueller Hinton Broth [147]. If this could not be achieved, hours
of growth delay for 20µM was depicted instead. +Anti-inflammatory activity refers to the peptide concentration (0.08-20 μM)
that significantly reduced TNF-α expression of murine macrophages, 2 hours after co-incubation with 100 ng/ml
lipopolysaccharide (LPS; E. coli) or 1 μg/ml lipoteichoic acid (LTA; S. aureus) [147]. If this could not be achieved, >20µM
was depicted instead.
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1.4.1.2 Cathelicidins: mechanisms of action and therapeutic potential
The cationic and amphipathic nature of cathelicidins is at the center of their
bactericidal properties [131, 140, 148–150]. These peptides can elicit a multitude of
antibacterial mechanisms, however, most can be classified as either 1) damaging the
bacterial membrane or 2) disrupting essential intracellular processes [131, 140, 148, 151,
152]. For the former pathway, the high diversity of cathelicidins has led to the creation of
several models, including the carpet-, toroidal- and barrel-stave models, that each
illustrate their interaction with the cell membrane in a different way [131]. For example,
utilizing lipid mixtures that mimic the composition of a bacterial membrane and
fluorescence spectroscopy, researchers have demonstrated that the pig cathelicidin
(PMAP-23) likely elicits its antibacterial properties by accumulating on or “carpeting” the
surface of the membrane [153]. It is speculated that at the core of these different models
is the electrostatic binding of the cationic cathelicidins to the negatively charged
phospholipids composing the bacterial membrane [131]. Specifically, this interaction has
been found to result in the peptides accumulating on or embedding in the cell membrane
[149, 154–156]. Consequently, this can cause either a detergent-like destruction of the
membrane, the formation of full cathelicidin-lined channels, or simply create holes in the
membrane [131, 140, 151, 156]. For example, additional fluorescence microscopy studies
have shown that the human cathelicidin (LL-37) “carpets” the bacterial membrane of
Escherichia coli, causing a global destruction of the membrane, yet utilizes a more
toroidal mechanism to create distinct pores in the membrane of Bacillus subtilis [157,
158]. Regardless of the exact method, the end result of these interactions with the
bacterial membrane is usually a loss of membrane integrity and eventually bacterial death
[146, 154, 159–163]. For the latter pathway, it has been demonstrated that some
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cathelicidins can enter the cytoplasm from the cell membrane and interact with
intracellular components, such as RNA, DNA, enzymes, as well as various chaperones
[140, 152, 156]. One such cathelicidin is indolicidin, a bovine cathelicidin that has been
found to permeabilize the membrane of E. coli without causing lysis, instead eliciting its
antimicrobial effects by inhibiting DNA synthesis [164]. The binding of these negatively
charged intracellular molecules has resulted in cathelicidins preventing aspects of protein
synthesis, cell division, DNA replication, nucleic acid biosynthesis, and a number of other
processes essential to bacterial survival [151, 152, 156, 165–169]. Through these two
main mechanisms, these positively charged peptides have retained antimicrobial activity
for millions of years [170].
It should also be noted that this multi-target approach to bacterial killing, makes
any single resistance mechanism likely ineffective against cathelicidins [171–174].
Further, avoiding cathelicidin-mediated disruption of the bacterial membrane would
require massive changes to its core elements and would likely come at the cost of normal
membrane function and structural integrity [140, 151, 173]. Moreover, the strong
negative charge of the bacterial membrane has been found to cause cathelicidins to
selectively interact with these microbes over the more neutrally charged eukaryotic cells
[131, 140, 175]. Together these factors help explain the current efficacy of these peptides
against AMR bacteria [169, 176–179] and support their potential as the next generation of
antimicrobial therapeutics [131, 172].
Beyond their direct antibacterial effects, cathelicidins have also been shown to
exhibit a diversity of immune-related functions that may be beneficial for treating lung
infections [141, 177, 180]. The exact effect, whether pro-inflammatory or antiinflammatory can vary greatly based on the presence of microbial by-products or the
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peptide itself. For example, LL-37 and the murine cathelicidin (CRAMP) have both been
found to skew macrophage polarization towards a more pro-inflammatory phenotype, yet
also reduce pro-inflammatory cytokine production in these macrophages in the presence
of bacterial by-products [141]. Additionally, the specific pathways involved in the
immunomodulatory effects of cathelicidins, require further study. However, they can be
broadly classified into directly or indirectly affecting chemokine production, apoptosis, or
chemotaxis of various immune cells, among other mechanisms [141]. Simply put, the
ability of these peptides to regulate the immune response goes well beyond their ability to
electrostatically bind negatively charged microbial by-products and prevent toll-like
receptor (TLR) activation [141, 177, 180]. In fact, in the context of bacterial lung
infections, even pro-inflammatory effects may be beneficial to help boost the immune
response and ensure proper elimination of bacteria in the lung. In summation, the wide
array of immune-related effects elicited by cathelicidins could promote a more balanced
rather than excessive immune response during infection, in addition to aiding bacterial
clearance.
Overall, the therapeutic potential of cathelicidins is quite diverse. For example,
cathelicidins have been shown to promote wound healing [181, 182], help regulate the
immune system [141, 177, 180], and combat a wide variety of pathogens, including
bacteria [155, 160, 172, 183], fungi [184, 185], viruses [186–188], and parasites [189,
190]. Many of these therapeutic properties could be of significant value for treating
bacterial pneumonia. However, this thesis will concentrate on the mechanisms of
bacterial killing and immune modulation through which these ancient peptides can help
combat AMR infections in the modern day [140, 141, 176, 177, 180, 191–195].
Additionally, despite their therapeutic promise, few cathelicidins or other antimicrobial
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peptides have been assessed in clinical trials [196]. Obstacles to development often
involve either toxicity towards eukaryotic cells (observed at high doses) or the loss of
activity due to environmental conditions in vivo [79, 180, 196–199]. Thus, to make these
peptides a clinical reality for pneumonia, preclinical studies are required to address
pulmonary delivery and toxicity challenges, as well as inhibitory interactions with
environmental factors. Lastly, the selection of an optimal cathelicidin for surfactant
delivery requires that the peptide has broad spectrum activity against clinically relevant
bacteria, such as P. aeruginosa, and resistance to environmental inhibition.

1.4.1.3 Chicken cathelicidin-2
Based on previous studies, one cathelicidin with properties suggestive of a strong
therapeutic potential is chicken cathelicidin-2 (CATH-2) [79, 137, 177, 180, 200, 201].
Originally called CMAP-27, CATH-2 is a 26 amino acid peptide found almost
exclusively in immune cells known as heterophils [138, 202]. It is one of four
cathelicidins identified in chickens and is cleaved into its active form by a serine protease
[137, 146, 202]. In terms of its antibacterial properties, CATH-2 has shown high efficacy
against a wide variety of clinically relevant bacteria, including P. aeruginosa and S.
aureus, independent of their resistance mechanisms to classical antibiotics [79, 137, 146,
177, 201, 203]. Live imaging studies, utilizing fluorescently labelled versions of CATH2, have also characterized its ability to rapidly permeabilize the bacterial membrane and
enter into the cytoplasm of both Gram-positive and Gram-negative bacteria [152, 156]. In
addition, in vitro and in vivo experiments have found that bacteria, such as P. aeruginosa,
do not elicit a pro-inflammatory response when killed by CATH-2, unlike other methods
of bacterial killing [180]. This immunologically silent killing of bacteria highlights the
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dual activity of this peptide for treating bacterial lung infections. Specifically, it has been
found to not only kill pathogens that target the airways, but also regulate the subsequent
host immune response [146, 177, 180, 192, 204]. Overall, CATH-2 has been shown to
have a diverse range of immunomodulatory properties, including its ability to
downregulate the recruitment of inflammatory cells and production of pro-inflammatory
chemokines in response to bacterial by-products [177, 192, 204]. This broad-spectrum
activity against AMR bacteria, in combination with its efficacy for immune regulation,
make CATH-2 an ideal candidate for treating bacterial lung infections.
Beyond its potency as an antimicrobial and anti-inflammatory agent, it should also
be noted that the activity of CATH-2 has been found to be more resistant to
environmental factors than other peptides. For example, at “high” salt concentrations the
potent antibacterial effects of many cathelicidins, including LL-37 and CRAMP, have
been found to be significantly reduced [199]. This salt sensitivity among these peptides
poses a major obstacle in their development as novel therapeutics for lung infections, as
similar salt levels are observed in the airways [205–207]. Complicating treatment further,
many respiratory conditions linked to chronic infections, such as CF are characterized by
even higher salt concentrations in the airways [205, 208]. In contrast, CATH-2-mediated
bacterial killing has been shown to be unaffected by “high” salt conditions [137, 146].
Additionally, the antibacterial effects of many cathelicidins, like LL-37 and eCATH-1
(horse) have also been shown to be inhibited by physiological levels of serum proteins
[180, 197]. However, under serum conditions that resulted in the complete loss of activity
for these other peptides, the potent bacterial killing of CATH-2 was found to be
unaffected [180]. This insensitivity to complex environmental factors, could be associated
with the unique structure of CATH-2 (Table 1.2). Specifically, the peptide contains a
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unique kink region, created by a proline residue at amino acid position 14 [146]. This
region has been shown to be essential to the therapeutic properties of CATH-2 and has
also been used to explain its greater retention of activity when combined with a surfactant
vehicle, compared to other cathelicidins [79, 146, 177]. Together, its resistance to
external factors, high potency against AMR bacteria, and various immunomodulatory
effects, make CATH-2 an ideal candidate for surfactant-based delivery in the treatment of
pneumonia.

1.4.1.4 Evaluating surfactant-cathelicidin mixtures
Our research group has previously evaluated surfactant-cathelicidin combinations
based on the antimicrobial functions of the suspended peptides. For example, bacterial
killing curves against various lab stains and clinical isolates have been utilized to
determine surfactant’s effect on the bactericidal properties of these peptides [79, 177]. In
general, these studies found that combining a cathelicidin with an exogenous surfactant
significantly inhibited its antibacterial activity [79, 177]. Further, despite their potency
against AMR bacteria, the antimicrobial effects of all cathelicidins tested, except CATH2, were found to be completely abolished when suspended in BLES [79, 177]. Although
the exact mechanism was not investigated, it was speculated that the reduction in bacterial
killing was likely related to the cationic nature of these peptides and their ability to
interact with the negatively charged phospholipids of the exogenous surfactant used [79].
This theory has been supported by a subsequent computer modeling study, but not
directly tested [209]. Thus, a better understanding for the inhibitory mechanism of
exogenous surfactants on cathelicidins, and the structural characteristics of CATH-2 that
allowed it to retain more of its antimicrobial activity, is required.
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Additionally, it should be noted that although there has not been any indication that
surfactant interferes with the anti-inflammatory properties of cathelicidins, there has also
been a lack of direct in vitro analysis. Specifically, there are no studies that have directly
compared the anti-inflammatory effects of a cathelicidin suspended in surfactant to the
peptide alone. In general, studies evaluating the immunomodulatory effects of these
peptides in combination with surfactant have been limited to overall efficacy in vivo
[177]. Therefore, better insight into the effects of surfactant on the immunomodulatory
properties of these peptides is needed.
Using various biophysical techniques, our research group has also performed studies
to evaluate the functionality of surfactant in surfactant-cathelicidin mixtures. One such
study, utilized the Langmuir probe and atomic force microscopy to demonstrate that
combining cathelicidins with bovine lipid extract surfactant (BLES) enhanced surfactant
spreading, through their ability to incorporate into the surfactant film [79]. However, in
the same study, biophysical analysis on a CDS revealed that this incorporation by some
cathelicidins, including CRAMP and LL-37, interfered with the ability of BLES to
achieve low surface tensions during cyclic compressions, whereas other peptides, such as
CATH-2 did not [79]. These findings have been further supported by a recent computer
modeling study, that utilized molecular dynamic simulations to reveal that antimicrobial
peptides, including LL-37 and CATH-2, can quickly penetrate the pulmonary surfactant
film [209]. These biophysical techniques were expanded upon in Chapter 2 to develop a
new in vitro screening tool for surfactant-based therapeutics, including surfactantcathelicidin preparations.
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1.4.2 Acute respiratory distress syndrome
In addition to bacterial pneumonia, a second respiratory condition that may benefit
from treatment with a surfactant-based therapeutic is ARDS. As touched on previously
(see section 1.2.4 Exogenous surfactant therapy), ARDS is defined by the physiological
criteria of severe lung dysfunction, that most commonly occurs after initiating insults,
such as sepsis or pneumonia, to the lung [47–49, 210]. The Berlin definition for ARDS
established specific diagnostic criteria for the syndrome, including a partial pressure of
oxygen/fraction of inspired oxygen (PaO2/FIO2) ratio of less than 300 mmHg with a
minimum of 5 cmH20 for positive end-expiratory pressure (PEEP) during mechanical
ventilation [47–49, 210]. It also created three different categories of ARDS (mild,
moderate, and severe) based on the severity of a patient’s hypoxemia [47–49, 210].
Overall, ARDS is a condition with a 30-50% mortality rate, whose treatment relies
heavily on mechanical ventilation strategies to improve survival [211–213]. Even before
the COVID-19 pandemic, it was the most common cause of death in the ICU and a large
burden on the health care system [210, 214–216]. Furthermore, to combat COVID-19
related ARDS, many researchers have begun to reconsider direct surfactant therapy and
its potential as a drug delivery vehicle [62].
Despite extensive research into the pathophysiological processes affecting the
initiation, development, and severity of ARDS, targeting these processes by
pharmacological intervention has been largely unsuccessful [214, 217–220]. Specifically,
there have been many drugs tested in clinical trials for ARDS that failed to demonstrate a
significant decrease in mortality, despite strong scientific evidence rationalizing their
potential benefits for treating the common processes associated with the disease [214,
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217–220]. These include, among many others, β2 agonist (to reduce edema), heparin (to
reduce fibrin deposition), antioxidants (to mitigate oxidative stress), exogenous surfactant
(to restore the surfactant system), and glucocorticoids (to downregulate the overwhelming
inflammation). Although a variety of aspects may have contributed to the lack of
pharmacological efficacies observed, drug deposition in the areas required for clinical
efficacy is certainly one important aspect. For example, many of the ARDS trials
mentioned utilized aerosolization as a drug delivery technique in which, as mentioned
above (see section 1.3 Exogenous Surfactant as a Drug Delivery Vehicle), results in drug
deposition mainly in the central airways rather than the alveoli [214, 217–220].
Moreover, drug distribution for inhaled therapeutics is also dependent on airflow. As
such, inhaled drugs will accumulate mainly in the inflated areas of the lung, whereas the
pathophysiological processes targeted by the drug occur in areas with edema which does
not receive airflow. These, as well as the added aspects of overcoming the endogenous
surfactant impairment and positive outcomes in ongoing clinical trials for surfactant
therapy, provide a strong rationale for utilizing a surfactant vehicle when testing
therapeutics for ARDS [62].
Further complicating treatment, ARDS is a complex and heterogenous disease,
whose pathological progression can vary greatly across patients [48, 210, 221–223]. For
example, ARDS from gastric acid aspiration may start with a chemical injury to the
epithelium and endothelium, leading to edema and surfactant dysfunction, followed by
pulmonary inflammation [210, 223–225]. In contrast, COVID-19 related ARDS likely
begins due to the infection of type II alveolar cell, whereas sepsis-induced ARDS is
initiated by systemic inflammation [213, 216]. Although the chronological order of these
pathological events is not always clear, there is a common final pathology, observed at
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the alveoli, in most forms of ARDS (Figure 1.3). Further, regardless of the underlying
processes or initiating events, it seems that overwhelming and maladaptive inflammation
in the lung is a main contributor to the disease [48, 221–223, 225, 226]. This dysregulated
pulmonary inflammation is manifested by inflammatory cell infiltration (predominately
neutrophils), secretion of proteases, inflammatory mediators, and reactive oxygen species
[48, 221, 222, 226, 227]. Additionally, this accumulation of activated leukocytes and
inflammatory mediators can cause damage to the respiratory units of the lung, as well as
alter the permeability of the alveolar-capillary barrier [223, 228, 229]. This could then
lead to edema and alterations to the endogenous pulmonary surfactant system, further
contributing to ARDS development [50, 51, 230]. Therefore, new therapeutic approaches
that can treat alveolar inflammation in ARDS patients would be of substantial therapeutic
value, regardless of the different pathophysiological pathways that could have led to the
condition.
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Figure 1.3. Schematic model of intratracheally administered drugs traveling through the
airways to arrive at the alveolar surface of a A) healthy or B) ARDS patient. In addition
to airway collapse prior to reaching the alveoli, the drug will also encounter various
pathologies at the alveoli of the ARDS patient, such as edema fluid, impaired surfactant
layer, impaired gas exchange, and inflammation. Inflammation includes neutrophil
infiltration and the release of inflammatory mediators.
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1.4.2.1 Glucocorticoids
A subclass of corticosteroids, glucocorticoids are found in mammalian species and
play an important role in many physiologic processes [231, 232]. Endogenously, these
steroid hormones are derived from cholesterol at the cortex of the adrenal gland and
regulated by the hypothalamic-pituitary-adrenal axis, in response to physiological stress
or the natural circadian rhythm [231, 232]. At the cellular level, their effects are mediated
through their binding with the glucocorticoid receptor (GR), found in the cytoplasm of
almost all human cells [232, 233]. The GR contains various structural domains important
for glucocorticoid binding, translocation to the nucleus, and DNA binding [234]. In the
absence of its “ligand”, it is kept in the cytoplasm as a multiprotein complex, where other
molecules cover its nuclear translocation regions [235]. As such, the binding of a
glucocorticoid causes the GR to dissociate from this multiprotein complex and translocate
into the nucleus of the cell [235, 236]. Once inside the nucleus, the activated
glucocorticoid receptor functions as a ligand-dependent transcription factor. Functionally,
glucocorticoids derive their name from their ability to increase serum glucose and as
such, regulate the metabolism of various macromolecules [231, 232]. However, they have
also been found to play an essential role in immune modulation, reproduction, water
homeostasis, general growth, as well as normal cardiovascular and cognitive function
[231, 232]. Although different glucocorticoids are produced across species, the main
physiologic glucocorticoid in humans is cortisol [231, 232]. As such, synthetic
glucocorticoids have been designed to structurally and functionally mimic cortisol [237].
This thesis will focus on the anti-inflammatory effects of pharmacologic glucocorticoids.
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1.4.2.2 Glucocorticoids: mechanisms of action and therapeutic potential
Clinically, the main therapeutic success of glucocorticoids has been in the
treatment of inflammatory diseases, such as asthma, arthritis, Crohn’s disease, and
ulcerative colitis (in addition to many others) [82, 237–240]. Specifically, the antiinflammatory effects of pharmacologic glucocorticoids are mostly attributable to their
ability to change the transcription state of genes in immune cells [238]. Briefly, the
glucocorticoid bound GR can affect gene expression directly, by binding DNA or
indirectly, through protein-protein interactions with other transcription factors [232, 233,
236, 238]. For the direct pathway, glucocorticoids can affect transcription by increasing
or decreasing the accessibility of DNA through chromatin remodeling, epigenetic
modifications, and the recruitment of coactivator complexes [241–245].For example, it
has been shown that the binding of this activated receptor to the promoter region of a
gene can promote [243, 246–248] or downregulate [249, 250] transcription by altering the
recruitment of transcription proteins, including RNA polymerase. For the indirect
pathway, glucocorticoids can affect gene expression by interacting with various proteins
and transcription factors to regulate signaling cascades [232, 243]. For example,
dexamethasone has been shown to elicit its anti-inflammatory effects by binding NF-kB,
Activator Protein-1 and Protein S (among others) [251–255]. Specifically, these studies
found that a therapeutic dose of dexamethasone suppressed the transcription for genes
encoding pro-inflammatory cytokines, chemokines, cell adhesion molecules, and various
enzymes involved in the inflammatory response [251–255]. Overall, these effects were
found to result in fewer leukocytes, such as neutrophils, emigrating into the site of
inflammation and promoted their clearance [251–255]. This potent efficacy for regulating
various aspects of the inflammatory response, combined with their relatively low cost and
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straightforward administration have lead to glucocorticoids becoming one of the most
prescribed medications in the world for treating inflammation [256–259].
Unfortunately, these highly effective drugs are not without their adverse side
effects [260]. Their potential for “off target” exposure is associated with their inherent
ability to pass through biological membranes and the universal expression of the
glucocorticoid receptor [232, 233]. Although not an exhaustive list, treatment with
systemic glucocorticoids has been associated with an increased risk of diabetes mellitus
[261, 262], serious infection [263–265], fractures [266, 267], and osteoporosis [268]. The
risk of these adverse effects was also found to increase in a dose and duration dependent
manner. However, glucocorticoid treatment strategies utilizing more targeted
administration methods have been demonstrated to increase efficacy and decrease rates of
adverse effects [82, 269–272]. Due to these advantages, it makes intuitive sense to
explore methods of direct delivery for glucocorticoids treating respiratory condition such
as ARDS.
The rationale for using surfactant-delivered glucocorticoids as a therapy for ARDS
was outlined, in general, in previous sections (see sections 1.3 Exogenous Surfactant as a
Drug Delivery Vehicle & 1.4.2 acute respiratory distress syndrome) and includes the need
for downregulating inflammation in the deeper regions of the lung. Briefly, the severe
lung dysfunction characterizing ARDS is thought to be a consequence of overwhelming
inflammation, and the subsequent pulmonary surfactant dysfunction, as well as edema at
the alveoli [48, 221–223, 225, 226]. Despite this strong rationale for anti-inflammatory
therapies in ARDS, glucocorticoids are not currently recommended for the disease [273,
274]. As shown in Table 1.3, this could presumably be due to most clinical trials with
glucocorticoids failing to reduce mortality rates among ARDS patients. However, it
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should be noted, that these studies used suboptimal methods to deliver glucocorticoids.
For example, the most widely used technique to administer glucocorticoids, systemic
administration, is affected by hepatic drug metabolism, renal clearance, and off-target
effects, which would all reduce efficacy [275]. Additionally, direct administration of
glucocorticoids via aerosol-based strategies has been shown to have limited utility in
ARDS, as delivery is determined by the airflow and CT-imaging studies in ARDS have
demonstrated a lack of lung inflation in injured regions [276, 277]. Thus, one
interpretation of these clinical trials is that the effectiveness of glucocorticoids was
limited by the lack of drug deposition at the alveoli. Lastly, as mentioned in a previous
section (see section 1.2.4 Exogenous surfactant therapy), exogenous surfactant therapy
has also been examined for patients with ARDS [46, 56–62]. Although initial metaanalyses of this therapy did not show an improvement in mortality, intratracheal
surfactant administration did improve oxygenation and lung compliance [60, 61]. This
latter improvement is indicative of its proposed function to reach and recruit collapsed
areas of the lung, as also demonstrated by animal studies [278–280]. Thus, in theory,
exogenous surfactant could overcome the delivery-hurdle encountered for glucocorticoids
in ARDS to allow the combination to become a desperately needed therapy for the
disease.

41
Table 1.3. Selected clinical trials with glucocorticoids for ARDS.

Glucocorticoid

Route of
Administrat
ion

Maximum
Dose
Administered
(per day)

Number of
Patients

*Mortality Rate
(Length of Study)

Methylprednisolone
[281]

Oral

2 mg/kg

24

No Significant
Change
(32-Days)
No Significant
Change
(60-Days)

Methylprednisolone

Intravenous

2 mg/kg

180

Methylprednisolone
[283]

Intravenous

1 mg/kg

27

Hydrocortisone
[284]

Intravenous

200 mg

149

Hydrocortisone
[285]

Intravenous

200 mg

197

Dexamethasone [286]

Intravenous

20 mg

277

Dexamethasone [287]

Intravenous

10 mg

299

Budesonide
[288]

Inhalation

2 mg

53

Budesonide
[289]

Inhalation

2 mg

60

[282]

Significantly
Reduced
(14-Days)
No Significant
Change
(21-Days)
No Significant
Change
(28-Days)
Significantly
Reduced
(60-Days)
No Significant
Change
(28-Days)
No Significant
Change
(15-Days)
Not measured
(3-Days)

*Mortality Rate refers to all-cause mortality at the final timepoint of the study.

Pulmonary Outcomes
Improvements in lung function and injury score
Increase in PaO2/FIO2 ratio
Increase in the number of ventilator-free days during
the first 28 days
Increase in PaO2/FiO2 ratio and lung compliance
during the first 28 days
Improvements in PEEP, with earlier extubation from
ventilation after 7 days
Increase in PaO2/FiO2 ratio after 7 days
No significant change in ventilator outcomes
No significant change in PaO2/FiO2 ratio
No significant change in ventilator outcomes
Increase in PaO2/FiO2 ratio after 7 days
Increase in the number of ventilator-free days
Increase in PaO2/FiO2 ratio at day 10
Increased number of ventilator-free days
Reduction of all markers of pulmonary fibrosis
measured at day 15
Increase in PaO2/FiO2 ratio after 11 days
Increase in PaO2/FiO2 ratio for 1st hour after
treatment
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1.4.2.3 Glucocorticoids: mechanisms of action and therapeutic potential
A glucocorticoid that has been studied extensively in combination with exogenous
surfactants is budesonide [78, 94–96, 290–295]. Budesonide is currently a mainstay
treatment for respiratory conditions, like asthma [83, 296, 297] and a variety of
inflammatory bowel conditions [298, 299]. It has also shown some clinical success in
treating various other obstructive airway diseases [83, 272, 300–302] and in combination
with formoterol, preventing ARDS development [303]. Additionally, budesonide
delivered by a surfactant vehicle has had success in clinical trials for BPD [92–95] and in
various animal models [94, 294, 295]. For example, in a piglet model of meconium
aspiration, budesonide combined with a porcine derived exogenous surfactant resulted in
improvements to a variety of inflammation-related outcomes, compared to surfactant or
budesonide alone [94]. Together, these studies demonstrate the potential for surfactantdelivered budesonide to be an effective treatment option for the alveolar inflammation
associated with ARDS.
Further supporting the potential of this mixture to treat ARDS are the specific
characteristics of budesonide. A synthetic, nonhalogenated 16,17-acetal steroid molecule,
budesonide has been found to have a topical anti-inflammatory potency 1000-fold higher
than the endogenous glucocorticoid, cortisol [304]. In fact, it was originally developed to
be a better, more selective intrapulmonary therapeutic for asthma [83], with higher local
activity and lower systemic bioavailability [83, 299, 304, 305]. Its minimal availability in
circulation and local selectivity for the lung, following inhalation, have been shown to be
linked to its interaction with lung enzymes and extensive first-pass metabolism [306,
307]. Moreover, although budesonide is moderately lipophilic, its retention and prolonged
activity in the airways have been found to be greater than similarly lipophilic
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glucocorticoids [83, 306, 308, 309]. Pharmacokinetic studies performed in vivo found that
these properties are linked to the rapid esterification of budesonide in the airways, by
coenzyme A [306–308]. Briefly, as explained by Van Den Brink et al., the subsequent
fatty acid conjugates of budesonide form intracellular deposits inside lung tissue [306].
Then, over an extended period the drug is released through the activity of intracellular
lipases. Furthermore, being slightly more water soluble than other inhaled glucocorticoids
budesonide has also been shown to display faster dissolution in bronchial fluid [84, 310].
Consequently, this has been found to result in a more rapid uptake of the drug into tissue,
with minimal removal from various clearance mechanisms in the lung [310]. Lastly, the
tendency of budesonide to have fewer off-target effects has been attributed to its rapid
metabolism by hepatic CYP3A enzymes and consequently, shorter systemic half-life [83,
308, 311, 312]. Specifically, this extensive first-pass metabolism seems to create inactive
metabolites of budesonide, that are easily excreted [83, 308, 311, 312]. Together, these
pharmacokinetic features give intratracheally administered budesonide a long duration of
local therapeutic effects with minimal systemic exposure [83, 313]. Thus, with a
surfactant delivery strategy, intratracheally administered budesonide could reach the
peripheral sites of inflammation associated with ARDS and be a long-awaited
pharmacological treatment for the disease.

1.4.2.4 Evaluating surfactant-glucocorticoid mixtures
As mentioned in the section above, the impact of glucocorticoids, notably
budesonide, on the function of various exogenous surfactants has been studied
extensively. Specifically, in vitro analysis has been used to investigate its incorporation,
transport, and overall effect on the surface tension lowering effects of different exogenous

44
surfactants [78, 290, 291, 293, 314]. For example, utilizing a captive bubble
surfactometer, budesonide has been shown to have a concentration-dependent effect on
the biophysical properties of the exogenous surfactant, Survanta, but not BLES [290].
The researchers found that high concentrations of budesonide were shown to significantly
inhibit the surface tension lowering properties of Survanta during compression and
reduced surfactant film stability [290]. Thus, the authors speculated that there was an
optimum type of exogenous surfactant and glucocorticoid concentration for this
interaction to occur without inhibiting the surface tension lowering properties of
surfactant. In a follow up study, utilizing the low cholesterol surfactant, Curosurf, it was
found that higher concentrations of budesonide would fluidize the surfactant film, without
altering the minimum surface tension achieved during compression [291]. Expanding on
the findings of the former study, the researchers inferred that combining glucocorticoids
with low cholesterol surfactants, like Curosurf or BLES would allow for larger amounts
of the drug to be delivered to the lung without compromising the surface activity of the
surfactant [291]. This theory was also supported by a recent wet bridge study, that utilized
a fluorescently labeled derivative of glucocorticoids, Beclomethasone Dipropionate to
evaluate drug transport by Curosurf [78]. When administered alone to the donor well, the
fluorescence of Beclomethasone Dipropionate was not detectable in the recipient well.
However, administering the drug with the low cholesterol exogenous surfactant resulted
in a significantly larger fluorescent signal for the recipient well [78]. From these results,
the researchers concluded that exogenous surfactant was an effective delivery vehicle for
corticosteroids, capable of efficiently transporting these drugs over the air–liquid
interface. Together, these in vitro studies showcase how the lipid composition of an
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exogenous surfactant and the concentration of the suspended glucocorticoid can affect
their interaction.
In contrast to the numerous in vitro studies analyzing the effect of glucocorticoids
on surfactant function, there has yet to be a study exploring the effects of this interaction
on glucocorticoid function. Moreover, animal studies with surfactant-glucocorticoid
mixtures have mainly focused on biodistribution within the lung, treating surfactant
deficiency, and the efficacy of this mixture as a prophylactic treatments for lung
inflammation [91, 293–295]. For example, a recent animal experiment, using a
radioactive derivative of the drug, 18F-budesonide, demonstrated that intratracheally
instilling budesonide with Survanta enhanced its biodistribution within the lung [293].
Further supporting this delivery approach for glucocorticoids, a study using a rabbit
model of meconium aspiration assessed the prophylactic efficacy of Curosurf combined
with budesonide [294]. The researchers found that prophylactic administration of this
combination alleviated lung inflammation more effectively than either the drug or
Curosurf alone [294]. Although these studies illustrate the benefits of exogenous
surfactants for enhancing the delivery and prophylactic efficacy of glucocorticoids, they
also highlight that additional experiments are required. The investigation of the antiinflammatory effects of a glucocorticoid alone or in combination with surfactant at a
distal site is explored in Chapter 2. In addition, Chapter 4 assessed the in vivo efficacy
of this combination when administered after an inflammatory insult has occurred in the
lung.
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1.5 Summary, Objectives, and Hypothesis
The complex branching structure of the airways makes direct delivery of
therapeutics to peripheral sites of inflammation and infection particularly difficult. This
delivery challenge has prompted the treatment paradigm for lower respiratory tract
conditions to move towards systemic dosing regimes. Unfortunately, these systemic
treatment strategies have been shown to be ineffective for inflammatory conditions like
ARDS and may even promote AMR among pneumonia patients. Moreover, systemic
dosing comes with the consequence of adverse side effects, largely avoided by routes of
direct delivery. Thus, there is an urgent need for novel delivery strategies, like
exogenous surfactant vehicles, that can promote a more localized drug distribution
to peripheral sites within the lung.
The overall objective of this thesis was to create a process for screening,
designing, and testing exogenous surfactants as delivery vehicles for specific
intrapulmonary therapeutics. The overall hypothesis was that exogenous surfactant
delivery would enhance the efficacy of antimicrobial cathelicidins and anti-inflammatory
glucocorticoids for the treatment of bacterial pneumonia and ARDS, respectively.
To test this hypothesis, Chapter 2 focused on the full characterization and utility
of the wet bridge transfer system, as an in vitro screening tool for surfactant-based
therapeutics. Chapter 3 implemented this system to further investigate the inhibitory
effects of exogenous surfactant on the antimicrobial cathelicidin function, as well as to
design a more ideal synthetic surfactant to deliver these peptides. Finally, Chapter 4
utilized a rat model of lung inflammation in both sexes to explore the therapeutic efficacy
of budesonide delivered by a surfactant vehicle compared to the drug alone.
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2.1 Introduction
Due to the complex branching structure of the lung, drug delivery to both the
proximal and distal regions of this organ remain a significant barrier for the delivery of
intrapulmonary therapeutics. Whereas nebulization can be utilized to effectively target
airways, it has limited utility for drugs that may require deposition to the distal alveolar
regions of the lung [1, 2]. Furthermore, the distribution of nebulized material is largely
determined by the flow of the inhaled gases and therefore may not be distributed equally
among all airways, in particular those that may be diseased. Clinical success for direct
endotracheal instillation of non-nebulized drugs has also been limited [3, 4], with several
pre-clinical animal models demonstrating that such delivery is primarily localized to the
central airways with little peripheral deposition [5–7]. Consequently, the vast majority of
pulmonary diseases are currently treated with high systemic doses of medications which
can either lead to suboptimal intrapulmonary efficacy or a high prevalence of systemic
side effects [8]. For example, conventional treatment of acute bacterial pneumonia, a
common disease of the peripheral airways, includes the empiric use of oral or intravenous
antibiotics. Treatment failure for this condition may result from inadequate tissue
concentrations, discontinuation due to systemic toxicity, or the induction of antibiotic
resistance due to insufficient killing properties. Thus, alternative strategies for targeted
pulmonary drug delivery are required.
One proposed strategy to overcome these challenges is through the use of
exogenous surfactant as a delivery vehicle, due to its unique biophysical properties. A
concept previously reviewed by Haitsma et al., (2001), these surfactants have the unique
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ability to efficiently and rapidly distribute throughout both the proximal and distal
airways [9]. Additionally, exogenous surfactants represent the current standard of care in
premature neonates in the setting of absolute or relative surfactant deficiency [10–13].
Furthermore, it has been shown in preclinical studies that certain therapeutics combined
with an exogenous surfactant have a significantly greater pulmonary distribution when
injected directly into the trachea of animals compared to the distribution of therapy alone
without a surfactant vehicle [14, 15]. Therefore, exogenous surfactants, like bovine lipid
extract surfactant (BLES), are promising candidates to facilitate pulmonary drug delivery.
Despite the theoretical advantages and promising preliminary animal studies,
surfactant-mediated drug delivery remains underutilized in clinical practice. The in vivo
data on surfactant as a carrier for agents instilled directly to the lung is limited, with few
in vitro experiments investigating the interactions between surfactant and drugs [16–20].
Moreover, the translation of exogenous surfactant into a multipurpose, clinically used
drug vehicle is hampered by the current testing methodology in which multiple
permutations of surfactant and drugs require expensive and laborious animal studies for
pre-clinical testing [9, 16, 17, 21].
Based on the above observations, the objective of this study was to develop and
test an in vitro technique to rapidly assess, screen and optimize surfactant-based therapies
prior to animal studies. This technique is based on methodology utilized in the study of
biophysics and consisted of a wet bridge transfer system. In the current study we utilize
this system to characterize surfactant spreading at different concentrations, volumes, and
temperature, as well as examining the effectiveness of surfactant as a carrier for
antibiotics and anti-inflammatory agents.
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2.2 Materials and Methods:
Reagents:
Pseudomonas aeruginosa (P. aeruginosa) ATCC 27853 (ATCC, Manassas, VA,
USA) was obtained from Sigma-Aldrich. gentamicin, colistin, and ciprofloxacin solutions
were all obtained from Sigma-Aldrich. Budesonide 0.5 mg/ml (AstraZeneca Södertälje,
Sweden) is a commercially available clinical preparation suspended in deionized water.
BLES 27 mg/ml phospholipid concentration (BLES Biochemicals, London, ON, Canada)
is a commercially available clinical surfactant preparation, stored in 1.5 mM calcium
chloride and 100 mM sodium chloride. Chicken cathelicidin CATH-2 was synthesized by
Fmoc (9-fluorenylmethoxy carbonyl) solid-phase synthesis chemistry. The peptide was
purified to a minimum purity of 95% by reverse phase high-performance liquid
chromatography prior to biological testing. The peptide was then suspended in nonbuffered sterile saline. For experimental use BLES was re-suspended in sterile saline to a
phospholipid concentration of 10 mg/ml, with 100 µM CATH-2, 50 µg/ml budesonide,
100 µg/ml gentamicin, 100 µg/ml colistin, or 100 µg/ml ciprofloxacin.

The Wet Bridge Approach:
The Wet Bridge Transfer System, schematically shown in Figure 2.1A, consisted
of a Teflon block with two 20mm diameter wells, a delivery well (Dish 1, D1) and a
remote well (Dish 2, D2). Each well has a depth of 1mm and was separated by a 0.2mm
high raised Teflon bridge. To measure surfactant mediated transfer, each well was filled
with 1 mL 150mM NaCl, 1.5mM CaCl2, and 5mM Hepes (pH 7.4) solution. Then a
continuous liquid interface between the two dishes was created using a 2cm x 0.5cm
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wetted piece of ashless filter paper placed over the Teflon bridge (Figure 2.1A). In this
system, therapeutics or other compounds can be injected into the delivery well, with
subsequent measurements of transfer in the remote well. The principle of the
methodology is that surfactant injected into the delivery well will be able to adsorb to the
air-liquid interface, and through its spreading capabilities, transfer over the wet bridge to
the remote well (Figure 2.1B). In contrast, drugs administered to the delivery well that are
not able to adsorb to the surface or spread across the wet bridge will therefore remain in
delivery well (Figure. 2.1C). If, however the drugs are mixed with surfactant they will
then be carried by the surfactant to the surface of the delivery well and transported over
the wet bridge to the remote well (Figure 2.1D).
Unless otherwise noted, our experiments were performed at room temperature
(24°C) using 200 µL of BLES (10 mg/ml) combined with various drugs/compounds:
colistin (100 µg/ml), gentamicin (100 µg/ml), ciprofloxacin (100 µg/ml), CATH-2 (100
µM), or budesonide (50 µg/ml). To assess the effect of temperature, the wet bridge
system was either put into a cold chamber (4°C), kept at room temperature, or placed into
an infant incubator (37°C).
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Figure 2.1. Schematic representation of the A) Wet Bridge Transfer System when a B)
surfactant, C) drug, or D) surfactant/drug mixture is administered to the delivery dish.

Functional outcomes on the Wet Bridge: Spreading:
Surface tension measurement using the Langmuir probe and FilmWare 2.51
software of the Langmuir balance was used to assess spreading of surfactant. The
Langmuir probe was dipped into the surface of D1 or D2 to monitor surface tension. The
surfactant samples were then administered to the delivery well and surface tension was
recorded over the subsequent 480 seconds.

Functional outcomes on the Wet Bridge: Bacterial Killing:
For bactericidal and anti-inflammatory experiments an overnight culture of P.
aeruginosa ATCC 27853 was grown in tryptic soy broth (TSB). Using measurements of
optical density (OD), 2x106 colony forming units (CFU) of bacteria were then either
stored in saline or seeded to the remote dish of the Wet Bridge Transfer system. Both the
delivery dish and remote dish were filled with 1mL of sterile saline and 200 µL of various
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antibiotics with or without surfactant were administered to the surface of the delivery
dish. Eight minutes after administration the wetted piece of filter paper was removed
using tweezers and all fluid was collected from both dishes and incubated at 37°C for 1
hour. Then 50 µL of each sample from the remote dish was diluted with 50 µL of saline
in a polypropylene coated 96-well plate and subsequently diluted 10-10 000-fold. CFU/ml
was determined by spot plating 10 µL of each dilution in triplicate on tryptic soy agar
(TSA) plates. These plates were incubated overnight at 37°C and colonies were counted
to a detection limit of 102 CFU/ml. Samples from the delivery dish were also spot plated
on TSA plates and incubated overnight at 37°C to ensure no bacterial transfer.

Functional outcomes on the Wet Bridge: Anti-inflammatory analysis:
RAW 264.7 murine macrophages were a kind gift from Wei-Yang Lu (Robarts
Research Institute, Western University, Canada). Cells were cultured in “complete growth
media” consisting of Dulbecco modified eagle medium (DMEM) supplemented with 10%
Fetal Bovine Serum (FBS) and 5% Penicillin/Streptomycin. Cells were seeded in 12-well
plates (3x106 cells/well) and allowed to grow to confluence overnight. They were
stimulated with 2x106 CFU/ml of heat-killed bacteria (90°C for 10 minutes) from the
overnight culture for 15 minutes prior to the administration of treatments. The ashless
filter paper was wetted with complete growth media and placed over the Teflon bridge
before the delivery dish and remote dish were filled with 1mL of complete growth media.
Then 200 µL of the CATH-2 or budesonide treatments were administered to the delivery
dish with or without BLES. Eight minutes after this administration the filter paper wet
bridge was removed with tweezers. Fluid from both dishes was collected and
administered onto the stimulated macrophages. The 12-well plates were then incubated
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for 4 hours at 37°C and 5% CO2. IL-6 levels were measured using an enzyme-linked
immunosorbent assay (ELISA) kit (BD Biosciences, San Diego, CA), according to the
manufacturer’s instructions.

Statistics:
The effect of different phospholipid concentrations on the surface tension
reducing properties of BLES was calculated using a two-way measure of analysis of
variance (ANOVA), followed by a Tukey-Kramer post hoc test using saline in Dish 1 or
Dish 2 as the control group. The influence of different volumes of administration and
temperature conditions as well as different therapeutics on surfactant spreading and
surface tension lowering properties were calculated using a one-way ANOVA, followed
by a Tukey-Kramer post hoc test using BLES at room temperature as the control group.
The efficacy of the surfactant/drug mixtures at the remote well was calculated by
analyzing CFU/ml or IL-6 content using a one-way ANOVA, followed by a TukeyKramer post hoc test, and using saline or BLES in Dish 2 as control groups. GraphPad
Prism 6 was used to graph and analyze data with a minimum of three independent
experiments per group. Means are reported + the standard deviation (SD), and values
were considered significantly different at a probability value (P) of less than 0.05.

2.3 Results
Spreading/Surface Tension:
Initial experiments characterized surfactant spreading on the wet bridge system by
administering different concentrations of BLES to the surface of D1 and measuring
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surface tension using a Langmuir probe in either D1 or D2. Figure 2.2AB shows the
change in surface tension over time in D1 and D2 following the administration of
surfactant to D1. For the first 30 seconds following the administration of surfactant the
surface tension in D1 and D2 showed an exponential drop in surface tension for
concentration greater than 1 mg/ml. Higher surfactant concentrations showed a further
decrease in surface tension during this initial period, but similar linear reductions in
surface tension during the remaining 7 minutes for both dishes. Quantification and
statistical comparisons of the minimum surface tension achieved during the 8 minutes
following administration is shown in Figure 2.2C. The data shows that all concentrations
of BLES achieved a significantly lower minimum surface tension compared to the saline
control in D1 and D2. Moreover, higher phospholipid concentrations of BLES achieved
significantly lower minimum surface tensions than the lower phospholipid concentrations
of BLES (Figure 2.2C). This was observed in both D1 and D2.
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Figure 2.2. Change in surface tension of A) Dish 1 and B) Dish 2 following administration of BLES to the surface of Dish 1.
Arrow indicates time of surfactant administration. C) Minimum surface tension achieved in Dish 1 and Dish 2 over the 480second period following surfactant administration. Statistical differences were determined by two-way ANOVA with TukeyKramer post hoc test. * p<0.05. Error bars = SD; n=3.
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To assess the effect of delivery volume, an experiment was performed in which
equal amounts of surfactant were delivered in different volumes to D1. The data shown
by Figure 2.3 illustrates that the minimum surface tension achieved in D1 or D2
following the injection of the different volumes was similar among the groups.

Figure 2.3. Minimum surface tension achieved over the 480-second period following the
administration of different volumes of surfactant with equivalent phospholipid content to
Dish 1. Statistical differences were determined using a one-way ANOVA with TukeyKramer post hoc test. * p<0.05. Error bars = SD, n=3.

To further characterize the wet bridge transfer system, the effect of three different
temperatures on the minimum surface tension achieved in D1 or D2 was tested using
various doses of BLES. Administration of surfactant at room temperature achieved
significantly lower minimum surface tensions in D1 compared to the low temperature (ice
chamber) condition at surfactant concentrations of 1, 5 and 10 mg/ml (Figure 2.4A).
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Instilling surfactant at room temperature achieved a significantly lower minimum surface
tension in D2 at surfactant concentrations of 1, 5, 10 and 20 mg/ml compared to the low
temperature condition (Figure 2.4B). Moreover, administering surfactant at the body
temperature (infant incubator) condition resulted in significantly lower minimum surface
tension readings compared to room temperature at surfactant concentrations of 1, 5, and
10 mg/ml for D1 (Figure 2.4A) as well as 1, 5, 10, and 20 mg/ml for D2 (Figure 2.4B).
The minimum surface tension achieved under the body temperature condition was
significantly lower across both dishes for all concentrations of surfactant compared to the
low temperature condition (Figure 2.4AB).
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Figure 2.4. Minimum surface tension achieved under low, room, and body temperature conditions in (A) Dish 1 and (B) Dish
2 over the 480 second period following surfactant administration. Statistical differences were determined using a one-way
ANOVA with Tukey-Kramer post hoc test. * p<0.05. Error bars = SD, n=3.
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Proof of principle experiment 1: Surfactant with Antibiotics:
To assess the influence of different antibiotics on surfactant spreading, the
minimum surface tension was calculated for each surfactant/antibiotic mixture in D2 over
the 8 minutes following administration to D1 and compared to the saline and BLES
controls. All surfactant/antibiotic preparations achieved significantly lower minimum
surface tensions compared to the saline control, but not significantly higher than
surfactant alone (Figure 2.5). Notably, the addition of colistin to BLES resulted in a
significantly lower minimum surface tension compared to the BLES control.

Figure 2.5. Minimum surface tension achieved in Dish 1 and Dish 2 over the 480-second
period following surfactant/antibiotic administration. Statistical differences were
determined using a one-way ANOVA with Tukey-Kramer post hoc test. * p<0.05. Error
bars = SD, n=3.
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To characterize bacterial killing at a distal site, antibiotics were administered
alone (solid bar) or in combination with BLES (dashed bar) to D1, and a colony counting
assay was performed in D2. Figure 2.6 shows that none of the antibiotics administered
alone to the delivery dish had any significant effects on the bacterial growth in D2
compared to either saline or BLES controls. However, BLES/gentamicin and
BLES/ciprofloxacin both showed significantly more bacterial killing in D2 compared to
the controls as well as gentamicin or ciprofloxacin alone (Figure 2.6). In contrast, colistin
showed no significant change in its bacterial killing when combined with BLES
compared to the saline, BLES or the antibiotic alone (Figure 2.6).

Figure 2.6. Bacterial killing in Dish 2 (2x106 CFU/ml P. aeruginosa) one hour following
administration of treatment to Dish 1. Statistical differences were determined using a oneway ANOVA with Tukey-Kramer post hoc test. * p<0.05. Error bars = SD, n=4.
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Proof of principle experiment 2: Surfactant with Anti-inflammatory drugs:
To evaluate the influence of different anti-inflammatory drugs on surfactant
spreading, the minimum surface tension was calculated for mixtures of surfactant
combined with either CATH-2 or budesonide in D2 and compared to saline and BLES
controls. The minimum surface tension achieved in the D2 by BLES/CATH-2 or
BLES/budesonide was significantly lower than the saline control (Figure 2.7).
Additionally, the minimum surface tension achieved by BLES/budesonide in D2 was not
significantly different compared to surfactant alone (Figure 2.7). However, the
BLES/CATH-2 preparation achieved a significantly lower minimum surface tension
compared to the BLES control in D2 (Figure 2.7).

Figure 2.7. Minimum surface tension achieved in Dish 1 and Dish 2 over the 480-second
period following surfactant/anti-inflammatory administration. Statistical differences were
determined using a one-way ANOVA with Tukey-Kramer post hoc test. * p<0.05. Error
bars = SD, n=3.
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To assess the ability of an exogenous surfactant to enhance drug delivery, the antiinflammatory properties of budesonide or CATH-2 in D2 were determined with either the
drug being administered alone (solid bars) or in combination with BLES (dashed bars) to
D1. The positive control signals for this experiment were created by stimulating
macrophages in D2 with heat-killed bacteria prior to the administration of either saline or
BLES to D1, creating a large IL-6 signal compared to unstimulated macrophages (red
dashed line). Furthermore, this data reveals that neither budesonide nor CATH-2
administered alone to D1 had any significant effect on the IL-6 content of D2 compared
to the positive controls (Figure 2.8). However, co-administration of BLES with either
budesonide or CATH-2 into D1 resulted in significantly lower IL-6 concentrations for D2
compared to the controls, budesonide, or CATH-2 alone (Figure 2.8).
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Figure 2.8. Anti-inflammatory effects of budesonide or CATH-2 alone or mixed with BLES on stimulated macrophages in
Dish 2. RAW264.5 macrophages (1x106 cells/ml) were stimulated with 2x106 CFU/ml of heat-killed P. aeruginosa 15 minutes
prior to administration of treatments to Dish 1. IL-6 content was measured 4 hours following administration of therapeutic
mixtures into Dish 1. Dashed red line indicates the IL-6 content for unstimulated macrophages. Statistical differences were
determined using a one-way ANOVA with Tukey-Kramer post hoc test. * p<0.05. Error bars = SD, n=6.
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2.4 Discussion
Exogenous surfactant has the potential to be an effective delivery agent for
pulmonary drugs, however clinical translation remains unfulfilled. The current study
illustrates the potential use of the wet-bridge transfer system as a tool to screen different
surfactant/drug preparations based on their ability to spread and elicit therapeutic effects
at a distal site. Herein, we demonstrate that spreading within this system was shown to be
dependent on surfactant concentration and temperature. Furthermore, utilization of the
system was illustrated using surfactant-antibiotic preparations in which surfactant showed
differing effects on different antibiotics and anti-inflammatory agents. It was concluded
that this technique can be utilized as an effective in vitro tool to screen and optimize
various surfactant-drug therapy strategies prior to in vivo testing.
The wet bridge transfer system we developed to test surfactant as a carrier of
various molecules for pulmonary delivery was based on previous descriptions of
biophysical studies examining surfactant lipid film. For example, the biophysical studies
performed by Yu & Possmayer (2003) used a transfer system to investigate surfactant
lipid transfer across an air-liquid interface. Additionally, Hidalgo et al., (2017) modified a
wet bridge system with a captive bubble surfactometer to determine whether surfactant
would be able to achieve and sustain low surface tensions when combined with
corticosteroids prior to compression−expansion cycling. Our study takes advantage of the
wet bridge system, but rather than solely focusing on biophysical properties, we explored
the transfer of clinically relevant therapeutics including antibiotics and anti-inflammatory
agents through functional outcomes at the transfer side of the bridge.
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The concept of enhancing pulmonary delivery for antibiotics through an
exogenous surfactant is appealing and has been previously investigated [2–4, 7, 9, 11, 16,
17, 23, 24]. Our data adds to this information as it illustrated that gentamicin,
ciprofloxacin, and colistin did not inhibit the spreading capability of surfactant, and only
gentamicin and ciprofloxacin elicited effects in the secondary dish when combined with
BLES. Thus, it can be speculated that exogenous surfactant would be a useful pulmonary
drug delivery vehicle to improve the distribution of these two antibiotic medications to
the more remote areas of the lung. In contrast, the inhibitory effect that surfactant exerted
on colistin appears to limit the usefulness of this antibiotic with surfactant, or
alternatively illustrates the need to further investigate drug-surfactant interactions to
optimize this combination.
Secondly, we investigated the use of the wet bridge transfer system to study the
transfer of anti-inflammatory compounds when combined with exogenous surfactant.
budesonide was chosen since it is currently being utilized in combination therapy with
surfactant for clinical use and its interaction with surfactant has been studied from a
biophysical and biocompatibility perspective [20, 25, 26]. The evidence provided here
with the wet bridge transfer system suggest that it can be used to further explore the
efficacy of other exogenous surfactants, and optimal dosing, without extensive animal
studies.
One of the key features of drug delivery by surfactant will depend on the nature of
the interaction between the surfactant and the specific drug being tested. Specifically, it is
essential that the drug is transported with the surfactant, but that the interaction does not
inhibit the innate function of either the surfactant or the drug itself. Previous studies have
indicated that the interactions between exogenous surfactants and therapeutics is
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dependent on either the lipid solubility of a drug or its ability to bind specific components
of surfactant, such as the phospholipids or surfactant associated proteins [27]. For
example, the second of our anti-inflammatory agents, CATH-2, is a positively charged
peptide which likely interacts with the negatively charged lipids of surfactant. This has
previously been shown to have a slight inhibitory effect on this peptide when testing its
other function, the ability to kill bacteria [18, 19]. It is feasible that the wet bridge system
could be used to develop a surfactant with a different lipid composition to optimize the
transfer and function of the surfactant-CATH-2 preparation.
Overall, our system for assessing surfactant as a carrier has several advantages
and potential usages. For example, any other drug that requires delivery to the distal
alveolar regions of the lung may be suitable for testing on this system, such as
combination of surfactant with drugs for pulmonary fibrosis, pulmonary hypertension or
primary lung cancers may have some therapeutic potential. In addition, delivery of other
compounds, like contrast agents for imaging studies, could also be investigated.
Furthermore, whereas our studies were performed using a sterile wet bridge and delivery
dish, other relevant in vivo conditions could be easily incorporated in this proposed set up.
Inclusion of serum proteins, to mimic edema, or proteases and lipases, to mimic
inflammatory environments, may be utilized to provide further insight into the properties,
interaction, and efficacy of surfactant drug combinations.
Despite the advantages of our proposed methodology, several limitations exist
which may be relevant. For example, one limitation of the technique is that the volume
and surface area of the two dishes does not reflect that of the extremely thin hypo-phase
of the lung. This requires therapeutics within our experimental setup to cross a much
larger distance through the hypo-phase within D2 to exert their therapeutic effects on the
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bacteria or macrophages. It would be possible, however, to build wet bridge transfer
systems with different size and depth for the delivery dish. The system is also limited by
the non-alveolar macrophages used in experimentation and the very simplified
unbranching path from “D1 to D2”. However, these limitations could easily be overcome
through the harvesting of alveolar macrophages from bronchoalveolar lavage (BAL) and
the construction of a wet bridge transfer system with multiple secondary dishes branching
from the delivery dish. It is also feasible to use the wet bridge and simply collect the
transferred surfactant-drug combination for further analysis of the experimental system.
Preliminary experiments for the current study were performed in this fashion and
provided a confirmatory series of experiments for the antimicrobial and antiinflammatory effects. The collection of transferred material in these experiments may also
allow for future compositional assessment. A second, more substantial limitation is that
the in vivo environment is much more complex than those environments tested with our
wet bridge. The wet bridge system detects the ability of surfactant to spread over a
relatively short distance whereas in vivo surfactant distribution is affected by more than
its spreading ability alone. Aspects like gravity, delivery volume, delivery technique, and
mechanical ventilation strategy (if employed) would all have an impact on the surfactantbased drug delivery. Certainly, the wet bridge transfer technique cannot eliminate in vivo
experimentation, however it does offer a relatively inexpensive approach to rapidly screen
surfactant/drug mixtures prior to animal, and ultimately clinical studies.

Conclusion:
From the data shown in the current study it can be concluded that the wet bridge
transfer system can effectively screen surfactant-based therapies through their spreading
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and efficacy at a remote site. Although, the system will always be limited by its ability to
imitate the physiological characteristics of an in vivo system, it offers the best method for
rapidly and accurately assessing surfactant based therapies in vitro [28, 29]. However
future animal studies are still needed to validate the findings of the wet bridge system and
to further investigate the distribution patterns and metabolism of these preparations in
vivo. Exogenous surfactants are promising delivering agents for pulmonary therapeutics
and are expected to improve drug distribution and drug efficacy for patients with
peripheral airway diseases. This direct delivery of medications to the airways, offered by
surfactant should increase local effectiveness and reduce systemic toxicity.
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3.1 Introduction
The increasing incidence of antimicrobial resistance (AMR) in bacterial
pneumonia has instigated a much-needed search for new therapeutic approaches for these
types of infections [1, 2]. One approach, involving the utilization of exogenous surfactant
for the delivery of antimicrobial peptides (AMPs) to the infected lungs is supported by a
strong theoretical foundation [3, 4]. The AMPs, such as the chicken cathelicidin, CATH2, can target a wide spectrum of antibiotic resistant bacteria, making them potential novel
therapeutics for bacterial pneumonia, which can be delivered to the areas of infection by
exogenous surfactant [3, 5–7]. Unfortunately, simply mixing CATH-2 or other AMPs
with a commercial exogenous surfactant has been shown to impact a drug’s therapeutic
efficacy [5, 8]. For example, we recently demonstrated that an exogenous surfactant with
CATH-2 exhibited antimicrobial activity against antibiotic-resistant bacterial isolates
from cystic fibrosis patients, albeit with less efficacy than CATH-2 by itself [5].
Therefore, in order to improve this promising approach, it is important to understand how
surfactant interferes with cathelicidin function and investigate strategies to minimize this
interaction, while maintaining the benefits of surfactant delivery.
The primary benefit of utilizing CATH-2, and other cathelicidins, for therapeutic
purposes is their diverse range of pathways to kill bacteria, since their positive charge
allows them to interact directly with both the negatively charged lipids of the bacterial
cell wall as well as intracellular targets such as DNA or RNA [9–12]. This multi-target
approach to killing bacteria has been demonstrated to be effective against a wide
spectrum of antibiotic-resistant organisms [5–7]. Unfortunately, the use of AMPs to treat
bacterial lung infections has been largely unsuccessful, due to an inability to directly
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deliver these peptides to the peripheral sites of infection [13–15]. Therefore, improving
the pulmonary delivery of these highly effective antimicrobial agents with an exogenous
surfactant would have substantial therapeutic value.
The goal of using exogenous surfactant for drug delivery is to open up collapsed
airways and areas with edema, in order for the therapeutic to reach the areas of the lung
affected by infection [16, 17]. Most commercially used exogenous surfactants are derived
from animal lungs and are complex mixtures of phospholipids (85%), neutral lipids (58%) and specialized surfactant proteins, designated SP-B and SP-C (7-10%) [17–19].
Although variations exist among different products, the main lipid components of these
exogenous surfactants are saturated (dipalmitoylphosphatidylcholine; DPPC, approx.
40%), unsaturated phosphatidylcholine (PC; approx. 35%), the negatively charged
phosphatidylglycerol (PG; approx. 10%), and neutral lipids like cholesterol (5-8%) [3].
These lipids, together with SP-B and SP-C are ultimately responsible for the ability of
exogenous surfactant to rapidly adsorb to the air-liquid interface and spread throughout
the airways [18, 20, 21].
Together, the above information on surfactant composition and cathelicidin
properties indicates that CATH-2 may interact with the negatively charged phospholipids
within surfactant. However, this has not been demonstrated directly, nor is there evidence
that this interaction interferes with cathelicidin function or if this interaction is crucial for
surfactant’s ability to act as a carrier for cathelicidins. It is hypothesized that the PG
component of surfactant inhibits CATH-2 function and that an exogenous surfactant, with
a reduced PG composition would increase peptide mediated killing at a distal site.
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3.2 Materials and Methods
Preparations:
The chicken cathelicidin, CATH-2 was synthesized and purified as described
previously [22]. It is comprised of 26 amino acids –
RFGRFLRKIRRFRPKVTITIQGSARF-NH2 and has a positive charge of +9 [23]. The
commercially available surfactant, bovine lipid extract surfactant (BLES) was generously
provided by BLES Biochemicals (London, ON, Canada). BLES was stored in 100 mM
sodium chloride and 1.5 mM calcium chloride with a phospholipid concentration of 27
mg/mL. Lipid enriched preparations of BLES were created through sonication at 37°C for
2 hours. The addition of 11.6 mg or 27 mg of individual lipids (DPPC, POPC, or POPG)
per mL of BLES created 30% or 50% lipid enriched versions of BLES respectively. The
SP-C peptoid protein mimic (mono-SP-C) utilized in the synthetic surfactants was
synthesized and purified (>97%) according to previously published protocols [24]. The
lipid and peptoid compositions of the synthetic surfactant preparations are summarized in
Table 3.1. All BLES preparations, lipid mixtures, and synthetic surfactants were used at
10 mg/mL phospholipid.

Bacterial killing curves:
Bacterial killing curves were performed as previously reported [5]. Briefly, an
overnight culture of Pseudomonas aeruginosa (P. aeruginosa; ATCC 27853), obtained
from Sigma-Aldrich (Oakville, ON, Canada), was grown in tryptic soy broth. Using
measurements of optical density, 2×106 colony forming units (CFU) of bacteria were
resuspended in saline. Varying concentrations of cathelicidins 0–20 µM were then mixed
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with either saline (No Lipids), BLES, individual lipid components at 1–2 mg/mL
phospholipid, lipid enriched BLES or a synthetic surfactant. These mixtures were then
incubated with the bacteria for 3 hours at 37°C before being serially diluted 10–10 000fold, with 10 µl of each dilution being spot plated in triplicate on tryptic soy agar (TSA)
plates. The plates were then incubated at 37°C overnight and counted the following
morning. No bacterial growth was designated as a bacterial concentration of less than 100
CFU/mL.

Isothermal titration calorimetry (ITC):
For ITC analysis, vesicles of POPC and POPG were generated using the extrusion
technique as previously reported [25]. Phospholipid content was determined as inorganic
phosphate after treatment with perchloric acid by UV-VIS spectroscopy[26]. POPC and
10%POPG/90% POPC vesicles were diluted to 1.5 mg/mL, while POPG vesicles were
further diluted to 0.15 mg/mL. For measurements using BLES, the stock solution was
diluted to 1.5 mg/mL. Interactions between CATH-2 and large unilamellar vesicles
consisting of POPC and/or POPG, or between CATH-2 and BLES were tested using ITC.
All ITC experiments were performed on a Low Volume NanoITC (TA instruments Waters LLC, New Castle, USA). In each experiment, the ITC cell chamber was filled
with 190 µl of vesicles or BLES, and the syringe was filled with a 50 µl solution of 320
µM CATH-2. Titrations were incremental with 2 µl injections at 300 seconds intervals.
Experiments were performed at 37°C and data were analyzed with the Nano Analyze
software (TA instruments - Waters LLC).
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Solid-State nuclear magnetic resonance (ssNMR) spectroscopy:
For ssNMR, DOPG unilamellar vesicles were prepared with 5 mM HEPES pH 7.5
and 50 mM NaCl by the extrusion technique and using filters with a 0.2 µm cut off[27].
Phospholipid concentration was determined as inorganic phosphate after treatment with
perchloric acid[28]. CATH-2 was added to DOPG vesicles to a final molar ratio of 1:50
CATH-2/DOPG. The interactions between CATH-2 and unilamellar vesicles of DOPG
were assessed using ssNMR. Vesicles were collected after ultracentrifugation and were
spun in 3.2 mm rotors. Static 31P ssNMR spectra were acquired at 500 MHz magnetic
field (1H-frequency) and a sample temperature of 295 K. Heteronuclear proton
decoupling did not affect the spectra and was switched off for all measurements. The
resulting 31P powder pattern was apodised with 50 Hz exponential line-broadening and
baseline corrected.

Bacterial killing and surface tension measurements on the wet bridge transfer system
To analyze surfactant spreading and bactericidal properties, the wet bridge
transfer system was set up as previously described[29]. The system consisted of a Teflon
block with two 20 mm diameter wells, a delivery well, and a remote well. Each well has a
depth of 1 mm and was separated by a 0.2 mm high raised Teflon bridge. A wetted piece
of ashless filter paper was placed over the Teflon bridge to join the delivery and remote
wells. Both wells were then filled with 1 mL of a 150 mM NaCl, 1.5 mM CaCl2, and 5
mM HEPES (pH 7.4) solution. To determine surfactant spreading, preparations were
administered into the delivery well and surface tension was measured in the remote well
using a Wilhelmy probe. FilmWare 2.51 software of the Langmuir balance was used over
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a period of 480-seconds after 200 µL of surfactant preparations or saline was
administered to the delivery well.
For bacterial killing experiments with the lipid enriched versions of BLES, the
overnight culture of P. aeruginosa was serially diluted to 2×105 CFU and seeded to the
remote well. Then 200 µL of cathelicidins (0-100µM) were administered to the surface of
the delivery well with saline, BLES or 30% lipid enriched BLES preparations. For
bacterial killing experiments with the synthetic surfactant preparations, the wet bridge
transfer system was modified through the addition of a lower sucrose layer. Both wells
were filled with 800 µL of a 10% sucrose solution (150 mM NaCl, 1.5 mM CaCl2, 5 mM
HEPES). Then 100 µL of the same solution without sucrose was added to make a thin
upper layer on top of the sucrose layer. For these experiments the overnight culture of P.
aeruginosa was serially diluted to 2×106 CFU of bacteria and seeded to the remote well
above the sucrose layer. For treatments, 100 µL of either saline, BLES or synthetic
surfactants with or without CATH-2 (100 µM) were administered to the surface of the
delivery well. Eight minutes after administration the wetted piece of filter paper was
removed, and all fluid was collected from both dishes to be incubated at 37°C for 3 hours.
Then 50 µL of each sample from the remote well was diluted with 50 µL of saline in a
polypropylene coated 96-well plate and subsequently diluted 10–10,000-fold. CFU/mL
was determined by spot plating 10 µL of each dilution in triplicate on TSA plates. These
plates were incubated overnight at 37°C and colonies were counted to a detection limit of
100 CFU/mL. Samples from the delivery dish were also spot plated on TSA plates and
incubated overnight at 37°C to ensure no bacterial transfer.
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Statistical Analysis:
All data points shown represent the average of at least three independent
repetitions. Statistical significance was determined by two-way analysis of variance and
one-way analysis of variance (ANOVA) followed by a Tukey-Kramer post hoc test to
determine differences among experimental groups. Results are presented as mean ± the
standard deviation and were considered statistically significant with a P-value of less than
0.05.
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Table 3.1. Lipid and peptoid compositions for synthetic surfactants.
Composition of Synthetic Surfactants
Surfactant

DPPC

POPC

POPG

Cholesterol

Mono-SP-C

Preparation

%Phospholipids

%Phospholipids

%Phospholipids

%Phospholipids

%Weight

20% POPG

35

40

20

5

2

10% POPG

35

50

10

5

2

5% POPG

35

55

5

5

2

2.5% POPG

35

57.5

2.5

5

2

0% POPG

35

60

0

5

2

Lipids only

35

50

10

5

0
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3.3 Results
Bacterial killing curves:
To investigate how exogenous surfactant and its lipid components affect
antimicrobial peptide function, bacterial killing curves were performed with CATH-2
combined with 10 mg/mL BLES or 1–2 mg/mL of individual surfactant lipids (Figure
3.1). Shown on each of the panels (Figure 3.1A–D) for comparison purposes, CATH-2
combined with saline (no lipids) exhibited potent bactericidal activity against P.
aeruginosa, reducing bacterial growth below detectable limits at 5 to 10 μM. In the
presence of 10 mg/mL BLES, the antimicrobial properties of CATH-2 were significantly
reduced at concentrations of 5 μM or greater (Figure 3.1A). Since BLES contains
approximately 10% PG, CATH-2 mediated killing was tested in the presence of 1 mg/mL
POPG. Similar to BLES, the presence of POPG at 1 mg/mL phospholipid significantly
reduced CATH-2 killing at concentrations of 5 μM or greater compared to the peptide
combined with no lipids (Figure 3.1B). Additionally, mixing CATH-2 with 2 mg/mL
POPG resulted in a complete loss of its bactericidal properties. In contrast to the effect of
POPG, there was no significant difference in the bacterial killing of CATH-2 combined
with DPPC or POPC at 1–2 mg/mL phospholipid, compared to the peptide with no lipids
(Figure 3.1CD). To explore if the PG effect was specific to CATH-2, killing curves for
CRAMP, PMAP-23 and LL-37 were also performed in the presence of BLES or
individual surfactant lipids. All three peptides showed complete inhibition of their
antimicrobial function when combined with 10 mg/mL BLES or 1–2 mg/mL POPG
(Figure 3.2A-C).

125

Figure 3.1. Killing curves for CATH-2 combined with BLES or individual surfactant lipids. Shown are the bacterial killing
curves for CATH-2 suspended in either A) BLES, B) POPG, C) POPC, D) DPPC or no lipids (saline). Colonies were counted
to a detection limit of 100 CFU/mL. *p<0.05 vs No Lipids. Error bars = SD; n=3.
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Figure 3.2. Bacterial killing for AMPs combined with individual surfactant lipids. Shown are the bacterial killing curves for A)
PMAP-23, B) LL-37, or C) CRAMP suspended in saline (No Lipids), BLES, POPG, POPC, or DPPC against 2x106 CFU/mL
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P. aeruginosa. Error bars = SD; n=3. Porcine PMAP-23, human LL-37 and mouse
CRAMP were all synthesized and purified as described previously [22]. Bacterial
colonies were counted to a detection limit of 100 CFU/ml. When combined with no lipids
each of the AMPs exhibited potent bactericidal activity. However, in the presence of
BLES or 1–2 mg/ml POPG the antimicrobial properties of all three cathelicidins were
completely abolished. There was no difference in the bacterial killing of any of the AMPs
in the presence of DPPC or POPC at 1–2 mg/mL phospholipid compared to the peptide
with no lipids.

To determine the effects of modifying an existing surfactant’s lipid composition
on cathelicidin function, bacterial killing curves were performed for CATH-2 mixed with
30–50% lipid enriched preparations of BLES (10 mg/mL). Suspension of CATH-2 in
30% or 50% POPG enriched BLES resulted in a complete loss of the peptide’s
antimicrobial properties (Figure 3.3A). However, at concentrations of CATH-2 of 5 μM
or greater, the 30% DPPC and POPC enriched BLES preparations were found to kill
significantly more bacteria than BLES/CATH-2, resulting in a 2–log reduction in
bacterial viability at 20 μM (Figure 3.3BC). At those concentrations of CATH-2, 50%
DPPC or POPC diluted BLES also showed significantly more bacterial killing compared
to their 30% equivalents.
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Figure 3.3. Antimicrobial activity of CATH-2 in lipid enriched preparations of BLES.
Displayed are the bacterial killing curves for CATH-2 suspended in 10 mg/mL of 30-50%
A) POPG, B) POPC, or C) DPPC enriched versions of BLES. Colonies were counted to a
detection limit of 100 CFU/mL. *p<0.05 for BLES + 30% lipid vs BLES, +p<0.05 for
BLES + 30% lipid vs BLES + 50% lipid. Error bars = SD; n=3.
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ITC and ssNMR of CATH-2 mixed with individual surfactant lipids:
To further examine the interactions between cathelicidins and exogenous
surfactant, CATH-2 and large unilamellar vesicles of individual lipids or BLES were
tested using ITC. As displayed in Figure 3.4A (bottom panel), there was no, or very little
heat production observed when CATH-2 was injected into the POPC sample, with an
enthalpy of -3.0 kJ/mol. However, when 10% POPG was added to the vesicles, a large
increase in heat production was observed following CATH-2 injection, indicative of
exothermic binding (Figure 3.4A; top panel; ΔH = -13.2 kJ/mol). For both BLES and
100% POPG vesicles, the binding of CATH-2 resulted in a 3–fold higher release of heat
(Figure 3.4B), with enthalpies of -34.6 and -34.2 kJ/mol respectively.
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Figure 3.4. ITC Binding of CATH-2 to vesicles and BLES. Shown are representative
thermograms of of ITC experiments with titration of 320 μM CATH-2, into 1.5 mg/mL
BLES, POPC and 10%POPG vesicles, or 0.15 mg/mL POPG vesicles.
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With ssNMR spectroscopy, CATH-2 combined with unilamellar vesicles of
DOPC and DOPG were assessed by acquiring 31P chemical shift anisotropy powder
pattern spectra under static conditions. These patterns result solely from the 31P chemical
shift anisotropy and are sensitive to both the lipid headgroup mobility and orientation[30–
32]. The addition of CATH-2 to the DOPG vesicles resulted in a modest but clear
broadening of the 31P powder pattern by 1.6 ppm (310 Hz) (Figure 3.5). For BLES the
addition of CATH-2 caused a broadening of the powder pattern by 2.6 ppm (470 Hz),
similar as in DOPG, demonstrating peptide-surfactant binding and modulation of the
surfactant headgroups. Lastly, isotropic signals were not observed for any of the
measurements, indicating that CATH-2 does not cause very strong curvature to the
membrane or the formation of spherical micelle-like structures (while curvature effects
could still modulate the 31P powder spectrum)[32, 33].
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Figure 3.5. ssNMR of CATH-2 mixed with BLES or liposomes. Static 31P solid-state NMR
spectra acquired at 500 MHz magnetic field. (upper panel) Spectra acquired with
unilamellar DOPG vesicles in the absence (black lines) or presence of CATH-2 (red lines).
The span of the powder pattern at approximately 10 % signal height is 42.6 ppm (8610 Hz)
and 41 ppm (8300 Hz) in the presence and in the absence of CATH-2, respectively. (lower
panel) Spectra were acquired with BLES surfactant in the absence (black lines) and the
presence of CATH-2 (magenta lines). The span of the powder pattern at approximately 10
% signal height is 59.7 ppm (12090 Hz) and 57.1 ppm (11560 Hz) in the presence and in
the absence of CATH-2, respectively. All spectra are normalised.
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Bacterial killing and spreading over the wet bridge for lipid enriched BLES:
To further examine the effect of PG on CATH-2 responses, BLES preparations
were enriched with individual lipids to change the relative percentage of PG within the
preparation. POPC and DPPC at 30 and 50% were utilized to decrease the relative PG
content, whereas POPG was used to increase the PG content within the BLES
preparation. Subsequently, the wet bridge transfer system was utilized to investigate if
CATH-2, suspended in lipid enriched preparations of BLES, delivered at a remote site
could affect bacterial killing, at a distal site. Suspension in BLES resulted in significantly
more bacterial killing by CATH-2 (20–100 µM) in the remote well, compared to the
peptide alone (Figure 3.6). CATH-2 (50–100 µM) suspended in 30% POPC enriched
BLES resulted in significantly more bacterial killing compared to BLES/CATH-2. When
mixed with 30% DPPC enriched BLES, CATH-2 (0–100 µM) displayed no change in
bacterial killing, compared to BLES/CATH-2. Additionally, the suspension of CATH-2
(50–100 µM) in 30% POPG enriched BLES resulted in significantly less bacterial killing
at the remote dish compared to BLES+CATH-2. Suspending the other AMPs, CRAMP,
PMAP-23, or LL-37 at 100 µM with 30% POPC enriched BLES were also shown to
significantly improve bacterial killing in the remote well compared to BLES/peptide or
the peptide with no lipids (Figure 3.7).
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Figure 3.6. Bacterial killing for CATH-2 over the wet bridge transfer system. Presented are the bacterial counts in the remote
dish (2x105 CFU/mL P. aeruginosa seeded) three hours following the administration of CATH-2, suspended in saline (No lipids),
BLES, or 10 mg/mL 30% lipid enriched versions of BLES, to the delivery dish. *p<0.05 vs BLES. Error bars = SD, n=3.
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Figure 3.7. Bacterial killing for cathelicidins over the wet bridge transfer system. Presented are the bacterial counts in the
remote well (2x105 CFU/mL P. aeruginosa seeded) three hours following administration to the delivery well of either saline
(No Lipids), BLES (10 mg/mL) or 30% lipid enriched versions of BLES (10 mg/mL) with or without CRAMP, PMAP-23, or
LL-37 at 100µM. *p<0.05 vs BLES. Error bars = SD, n=3. When combined with 30% POPC enriched BLES all three peptides
killed significantly more bacteria in the remote well compared to BLES or no lipids.
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To examine the spreading characteristics of the 30% lipid enriched preparations of
BLES, the surface tension in the remote well of the wet bridge was measured over a 480
second period after instillation into the delivery well. All 30% lipid modified mixtures of
BLES achieved surface tensions significantly lower than saline (Figure 3.8). However,
the surface tension achieved by 30% DPPC or POPC diluted BLES were significantly
higher than BLES alone.

Figure 3.8. Surfactant spreading over the wet bridge transfer system for lipid enriched
BLES. Shown are the surface tensions achieved in the remote dish after the 480-second
period following administration of saline, BLES (10 mg/mL) or 30% lipid enriched
preparations of BLES to the delivery dish. *p<0.05 vs BLES. Error bars = SD; n=4.
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Bacterial killing curve for synthetic surfactants:
To further explore the inhibitory effects of PG and the potential of a PG-free
surfactant, bacterial killing curves were performed for CATH-2 combined with synthetic
surfactants of varying PG content. At CATH-2 concentrations of 5 μM and above,
bacterial killing was found to be significantly greater for synthetic surfactants with 5% or
less POPG and significantly lower for preparations with 20% POPG compared to BLES
(Figure 3.9). The synthetic surfactant with a POPG composition of 10% displayed similar
bactericidal properties to BLES when combined with CATH-2 at 0–20 μM. Lastly,
combining CATH-2 with PG-free synthetic surfactant (0% POPG) resulted in
antimicrobial properties no different than the peptide alone.
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Figure 3.9. Bacterial killing curves for CATH-2 combined with synthetic surfactants.
Shown are the bacterial killing curves for CATH-2 suspended in saline (No Lipids), 10
mg/mL of BLES or synthetic surfactant with varying PG content. Colonies were counted
to a detection limit of 100 CFU/mL. The composition of all synthetic surfactants is
displayed in Table 1. Error bars = SD; n=3.

Bacterial killing and spreading over the wet bridge for synthetic surfactants:
To examine the spreading characteristics of the synthetic surfactants, the surface
tension in the remote well of the wet bridge was measured over a 480 second period after
instillation into the delivery well. All of the synthetic surfactants tested achieved surface
tensions similar to BLES and significantly lower than saline or the lipids alone (Figure
3.10).
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Figure 3.10. Spreading over the wet bridge transfer system for synthetic surfactants.
Shown are the surface tensions achieved in the remote dish after the 480-second period
following administration of saline, lipids only, BLES (10 mg/mL) or a synthetic
surfactant preparation to the delivery dish. *p<0.05 vs BLES. Error bars = SD; n=4.

To further evaluate the efficacy of a PG-free synthetic surfactant for delivering
AMPs to a distal site, CATH-2 (100µM) was administered to the delivery dish of the wet
bridge transfer system with no lipid, BLES or in combination with a synthetic surfactant.
Administering CATH-2 with BLES or the 10% PG synthetic surfactant showed similar
bacterial killing at the remote well (Figure 3.11). CATH-2 suspended in a PG-free
synthetic surfactant resulted in significantly more bacterial killing in the remote well than
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all other preparations mixed with the peptide. This data implies that the synthetic
surfactant without PG was capable of spreading over the wet bridge and acting as a
carrier for CATH-2 to induce killing at a remote location.

Figure 3.11. Bacterial killing over the wet bridge for synthetic surfactants/CATH-2.
Presented are the bacterial counts in the remote dish (2x106 CFU/mL P. aeruginosa
seeded) three hours following administration to the delivery dish of either saline (No
lipids), BLES, or synthetic surfactants with or without CATH-2. ap<0.05 vs BLES,
b

p<0.05 vs 10% PG synthetic surfactant, *p<0.05. Error bars = SD; n=9-11.

3.4 Discussion
The current study tested the hypothesis that the PG component of surfactant
inhibits CATH-2 function and that an exogenous surfactant with a reduced PG
composition would increase peptide mediated killing at distal sites. Overall, our results
supported this hypothesis. Specifically, measurements of bacterial killing as well as both
assessments of binding indicated that PG interacts with CATH-2, inhibiting its function.
Furthermore, reducing or eliminating the PG content in an exogenous surfactant improved
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the ability of CATH-2 to kill bacteria. It was also shown that a PG-free synthetic
surfactant was capable of carrying CATH-2 to distal sites to kill bacteria. Based on these
observations it is concluded that synthetic PG-free surfactants will enhance the
pulmonary delivery of CATH-2 without inhibiting its antimicrobial function.
Clinically, the relevance of this study is associated with the potential positive
benefits of treating bacterial lung infections with cathelicidins delivered by a surfactant
vehicle to reach the deeper areas of the lung. For many pneumonia patients, the
acquisition of antimicrobial resistant bacteria represents a decisive stage in disease
progression, towards poor outcomes [34–38]. The ability of CATH-2 and other AMPs to
target antibiotic resistant bacteria make these molecules interesting for the development
of novel therapeutics [11, 39, 40]. The ability of exogenous surfactants, to re-open
collapsed airways and allow antimicrobials access to regions blocked off during the
infection will also be essential for combating resistance [41–43]. The direct delivery of
antimicrobials will elevate local therapeutic concentrations at the pulmonary sites of
infection, improving bacterial clearance and limiting the development of resistance [15,
44]. Together, CATH-2 and exogenous surfactant represent a desperately needed
treatment strategy to address the growing threat of multidrug-resistant lung infections.
An important aspect of the current paper was the utilization of a synthetic PG-free
surfactant, customized for its ability to maintain CATH-2 activity. Several molecular
dynamic simulations have suggested that cathelicidins would electrostatically bind the
anionic lipids in bacterial membranes[45–48]. Similarly, NMR studies have also
demonstrated that AMPs have a strong tendency to form helical structures that bind
negatively charged molecules, such as the lipopolysaccharides of Gram negative bacteria
[49, 50]. Altering such electrostatic interactions, through additional anionic lipids, lipid
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lysinylation, or changes to the cationic nature of the peptide, have all been shown to alter
bacterial killing [51–54]. In support of these observations, our ssNMR, ITC and bacterial
killing data provides strong evidence that PG was the inhibitory component of the
exogenous surfactant, likely by restricting CATH-2 from directly or indirectly binding
negatively charged lipids, DNA or other bacterial components [11, 40, 55]. Moreover, the
enhancement in CATH-2 function following the addition of POPC or DPPC to BLES,
illustrates the potential benefit for lowering PG content in surfactant to reduce
electrostatic interactions with these peptides. As such, we generated a PG-free surfactant
using a surfactant protein mimic of SP-C and demonstrated that such a surfactant, mixed
with CATH-2, was significantly better at killing bacteria at a remote site compared to PGcontaining surfactants. Since AMPs have been shown to form weak hydrophobic
interactions with neutral lipid membranes [56–58] it is likely that the PG-free preparation
transported CATH-2 via these weaker hydrophobic interactions. Importantly, this weaker
binding likely allowed CATH-2 to still interact with the bacteria at the remote site. Thus,
we conclude that synthetic PG-free surfactants are optimal delivery vehicles for CATH-2
and that it is worthwhile investigating such therapeutics in future in vivo studies.
The generation of a PG-free surfactant for the delivery of CATH-2 also provided
proof of a more general concept, that synthetic surfactants can be customized for drug
delivery. The majority of studies exploring surfactant as a carrier of pulmonary antibiotics
and other pulmonary therapeutics simply mix the drug with a commercial exogenous
surfactant preparation developed for the treatment of surfactant deficient premature
infants rather than as a delivery vehicle [3, 16, 29, 41, 59]. Although some success has
been obtained with these approaches [3], many of the surfactants utilized were animal
derived preparations in which the composition is established by its endogenous source.
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The advantage of a synthetic surfactant is that the specific composition can be optimized
for the delivery of drugs. We utilized an approach of using surfactant protein mimics, or
peptoids, since a recent study demonstrated that these peptoid-based surfactant were not
only active in vivo, but equivalent to animal-derived surfactants for improving
oxygenation and other physiological outcomes in a model of acute lung injury [60].
Peptoids are structurally based on a polypeptide backbone but with side-chains appended
to nitrogen-backbone, they are highly stable to proteolysis and can be made in high yields
[24, 61, 62]. Once synthesized, the peptoids can also be easily mixed with a specific lipid
mixture optimized to spread throughout the lung and for drug delivery, as illustrated in
vitro with our PG-free surfactant. Overall, we propose that the development of peptoids
and other synthetic analogs of the hydrophobic surfactant proteins will allow for a more
mechanistic approach to developing surfactant-based drug delivery approaches.
Having established the effect of exogenous surfactant on CATH-2, there is also
therapeutic value in exploring if similar approaches can be utilized for other cathelicidins,
thereby increasing the clinical arsenal of antimicrobial agents. Unfortunately, the
presence of exogenous surfactant completely abolished the antimicrobial function of
many cathelicidins, including human LL-37, mouse CRAMP and pig PMAP-23 [8].
However, the current study combined each of these peptides with a lipid enriched
preparation of surfactant and demonstrated that they could all benefit from delivery by a
surfactant with a reduced PG content. This ability to create functional exogenous
surfactants, that minimally interact with a variety of AMPs, will substantially increase the
treatment options for lung infections. For these reasons, developing exogenous surfactant
as a delivery vehicle for multiple AMPs, each with their own unique antibacterial
pathway, would create a promising new pipeline of anti-infective therapeutics.
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It should also be noted that there are several limitations to our study. First, the
bacterial killing was limited to one strain of bacteria. However, it is important to note that
our previous study showed a similar pattern of inhibition for CATH-2, by surfactant
against several Cystic Fibrosis derived bacterial strains. As such, we anticipate that PGfree surfactant with CATH-2 will likely provide improved killing activity against other
strains as well [5]. Secondly, the PG-free synthetic surfactant was only tested in
combination with one cathelicidin, CATH-2. However, we did demonstrate that several
other cathelicidins were also inhibited by PG and benefited from a lipid enriched
surfactant with a reduced PG composition. From these findings, we predict that LL-37,
CRAMP, and PMAP-23 would all benefit from delivery by a PG-free synthetic
surfactant. It should also be noted that high concentrations of AMPs have been associated
some cytotoxic effects towards mammalian cells, potentially limiting their therapeutic
potential [8, 63–65]. However, a recent in vivo study showed that co-instillation of
CATH-2 with an exogenous surfactant was well tolerated, with no deleterious effects up
to 100 µM [8]. Lastly, our synthetic PG-free surfactant was only designed based on
minimizing PG content. The preparation contains POPC, DPPC and cholesterol as well as
a SP-C peptoid, however, this composition could be further optimized with respect to
these remaining components as well as other surfactant components.
In conclusion, this paper has demonstrated how exogenous surfactant can be
designed to be a more effective delivery system for CATH-2. Further, we propose that
this concept could be applied to other intrapulmonary therapeutics. Direct drug delivery is
a major hurdle for many pulmonary conditions and designing exogenous surfactants with
specific drug-delivery properties offers an intriguing method to overcome that obstacle.
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4.1 Introduction
Inflammation is associated with many respiratory conditions, including asthma,
pneumonia, bronchopulmonary dysplasia (BPD), and Acute respiratory distress syndrome
(ARDS). However, the effectiveness of anti-inflammatory medications – such as
glucocorticoids – is location-specific for these conditions in terms of airway (bronchi) or
airspace (alveolar) involvement [1]. In asthma, for example, inflammation is observed
primarily in the small airways, which allows for a more direct delivery of therapeutics, as
evidenced by the effectiveness of standard inhalers [1, 2]. On the other hand, in
conditions such as ARDS and bacterial pneumonia, inflammation occurs in the more
distal, alveolar, regions of the lung [1, 3, 4]. Here, the large surface area, and associated
regions of alveolar edema or airway collapse may contribute to an inability of airwaydelivered therapies to reach distal lung units, to provide effective anti-inflammatory
functions [1, 3, 4]. In these clinical scenarios, alternative strategies are required to deliver
therapeutic concentrations of anti-inflammatory medications to these peripheral sites
within the lung.
One such approach, is with the use of exogenous surfactant as a delivery vehicle
for glucocorticoids such as budesonide. Exogenous surfactant is a complex mixture of
lipids and specialized proteins, usually obtained from natural sources such as cows or pigs
[5]. The endogenous material, produced by type II alveolar cells in the lung, has been
well studied and serves a vital biophysical role in reducing surface tension, thereby
stabilizing the alveoli during normal breathing [6, 7]. The discovery of surfactant
deficiency in preterm infants led to the development of exogenous surfactant therapy [8].
Given intratracheally, it spreads throughout the lung, improving lung function and has
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resulted in significant reductions to infant mortality due to prematurity [8, 9]. It is
suggested that the spreading properties of exogenous surfactant could improve
glucocorticoid delivery to peripheral sites of inflammation in the lung. In support of this
notion, exogenous surfactant has already been shown to enhance the delivery of
glucocorticoids to remote sites using in vitro approaches [10–12]. Additionally, it has
been shown that through these properties exogenous surfactant can re-open collapsed
airways, overcome regions of edema, and efficiently spread to the more remote sites of
inflammation in an injured lung [6]. Together, this data highlights the potential for
exogenous surfactant to provide locally acting anti-inflammatory drugs access to remote
regions of the lung otherwise inaccessible to therapeutics.
When combined with the efficacy of glucocorticoids, the innate biophysical
properties of surfactant suggest that utilizing exogenous surfactant as a vehicle for
budesonide would improve its effectiveness for treating remote inflammation in the lung.
However, this has yet to be demonstrated in vivo. It was therefore hypothesized that
fortifying an exogenous surfactant with budesonide would enhance efficacy for treating
pulmonary inflammation in vivo.

4.2 Materials and Methods
Reagents
Heat-killed bacteria (HKB) was created from a lab strain of Pseudomonas
aeruginosa (P. aeruginosa; ATCC 27853), purchased from Sigma-Aldrich (Oakville, ON,
Canada). Using measurements of optical density, the bacteria was diluted in saline to 3x106
colony forming units per ml, before being heated at 90ºC for 15 minutes. A commercially
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available preparation of budesonide (0.5 mg/ml), suspended in deionized water, was
obtained from AstraZeneca (Södertälje, Södermanland, Sweden). Bovine lipid extract
surfactant (BLES) at 27 mg/ml phospholipid concentration was obtained from BLES
Biochemicals (London, ON, Canada).

Animal models and treatments
All animal work was carried out in accordance with guidelines set forth by the
Western University Council for Animal Care. For breeding, two adult male and seven adult
female Wistar rats (250 g) were purchased from Charles River (St-Constant, QC, Canada).
Acclimatization to the animal care facility and breeding were carried out as previously
described [13]. Once pregnant, rats were housed individually and received standard chow.
Immediately after birth the litters were culled to 10 pups in order to limit the effect of litter
size on outcomes.
To initiate pulmonary inflammation, male or female offspring were weighed,
anesthetized, and intratracheally instilled with 2 µl of HKB or saline per gram of body
weight at 25-35 days of age. In animals randomized to a treatment group, this first
instillation was followed by an instillation of either budesonide (50µg/ml) or
BLES/budesonide (10mg/ml; 50µg/ml). To minimize the potential effects of any distinct
litter, only 1 or 2 animals per litter were randomized to any individual experimental group.
Animals were monitored for 6 hours following instillation, before being euthanized by
intraperitoneal injection of sodium pentobarbital and exsanguination, by severing the
descending aorta. After this, a bronchoalveolar lavage (BAL) was performed as previously
described [14], before the lungs were excised, divided into four pieces and snap frozen in
liquid nitrogen to be stored at -80ºC.
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Outcomes
Inflammatory cell counts and differential cell analysis of the lavage were done as
previously described [14]. Briefly, lavage volume was recorded and centrifuged at 150 x g
for 10 minutes to obtain a cell pellet. This pellet was resuspended and used for cell counting
and differential analysis to obtain the number of inflammatory cells and neutrophils in the
BAL. Protein content of the BAL was also measured using a Micro BCA protein assay kit
from Pierce Biotechnology (Rockford, IL, USA), per manufacturer’s instructions. A
multiplexed immunoassay kit was utilized per manufacturer’s instruction (R&D Systems,
Minneapolis, MN) to measure the concentrations of TNF-α, IL-6, MIP-2 and GRO/KC. A
Bio-Plex 200 readout system was utilized from Bio-Rad (Santa Rosa, CA, USA) and
cytokine levels (pg/mL) were automatically calculated from standard curves using BioPlex Manager software (v. 4.1.1, Bio-Rad). An aliquot of the 150 x g supernatant was also
analyzed through a Duck-Chong phosphorous assay as previously described [15]. Briefly,
the total amount of surfactant in the lavage was determined through the measurement of
phospholipid-phosphorus [16, 17]. The remainder of the supernatant was then centrifuged
at 40,000 x g for 15 min to obtain a pellet of the active form of surfactant, the large
aggregates. This resuspended pellet, as well as its supernatant containing the small
aggregates, was also analyzed for phospholipid-phosphorus [16, 17].

Frozen lung tissue was utilized for myeloperoxidase (MPO) activity as previously
described [18]. Briefly, pieces of frozen lung were weighed and then homogenized in 0.02
M potassium phosphate buffer (pH 6; Sigma-Aldrich) using a PT2100 homogenizer. Lung
homogenate was spun at 6000 x g for 20 minutes at 4ºC, with the resulting pellet being
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resuspended in 1% hexadecyltrimethylammonium hydroxide detergent solution. This
mixture was then re-homogenized, before being sonicated at 4ºC and 30% amplitude for
10 seconds. The resulting preparation was spun at 13,000 x g for 10 minutes at 4ºC. Its
supernatant was then aliquoted into a 96-well plate at 2 mg/ml and mixed with an MPO
cocktail containing 3,3',5,5'-tetramethyl-benzidine. Hydrogen peroxide was then added to
each well and the plate was incubated at 37ºC for 5 minutes. Sulfuric acid was used as a
stop solution and the plate was read at 450 nm using an iMark plate reader (BioRad). MPO
activity (units/mg) was calculated from standard curves.

Statistical Analysis:
All data points shown represent one male or female rat. Statistical significance was
determined by two-way analysis of variance (ANOVA), followed by a Tukey-Kramer
post hoc test to determine differences among experimental groups. Results were
considered statistically significant with a P-value of less than 0.05.

4.3 Results
Baseline characteristics of the experimental groups are shown in Table 4.1. Prior to
the first instillation, body weights were found to be similar among the experimental groups.
There were also no significant differences across groups for protein content in the BAL.
The phospholipid composition of surfactant, including total surfactant, as well as the large
aggregate and small aggregate sub-fractions were significantly higher in male and female
rats receiving BLES/budesonide compared to all other treatment groups.
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Table 4.1. Baseline characteristics for male or female rats in each treatment group.

Saline

Number of
Animals
Body
Weight
Protein

HKB
+
Budesonide

HKB

HKB
+
BLES/Budesonide

Males

Females

Males

Females

Males

Females

Males

Females

7

9

8

9

7

9

8

9

93.8 ±
8.2

88.7 ±
11.8

93.3 ±
6.9

85.1 ±
4.7

93.0 ±
11.4

87.3 ±
8.5

95.1 ±
13.2

86.7 ±
8.5

23.8 ±
10.7

19.6 ±
9.2

19.2 ±
7.7

21.7 ±
5.7

20.1 ±
6.3

17.7 ±
7.9

21.6 ±
6.2

23.9 ±
9.9

12.0 ±
2.2

10.7 ±
1.7

11.5 ±
1.9

10.8 ±
2.1

11.0 ±
2.2

16.6* ±
2.8

17.2* ±
3.1

6.9 ± 1.2

6.3 ± 1.2

7.0 ± 1.3

8.2 ± 2.3

7.4 ± 2.1

9.7* ±
2.3

10.9* ±
3.4

5.1 ± 1.1

4.7 ±
1.2

3.8 ± 0.9

3.1 ± 1.4

3.9 ± 1.5

7.0* ±
2.8

6.1* ±
1.9

Total
Surfactant
10.3 ±
(mg/kg
2.0
BW)
Large
Aggregates
6.1 ± 1.3
(mg/kg
BW)
Small
Aggregates
4.4 ± 0.9
(mg/kg
BW)

*p<0.05 vs saline.

To evaluate the anti-inflammatory effects of delivering budesonide with an
exogenous surfactant, standard inflammatory markers were analyzed using BAL and
frozen lung tissue. The instillation of HKB resulted in a significantly higher number of
inflammatory cells compared to saline (Figure 4.1). The instillation of budesonide,
following HKB, did not have a significant effect on the number of inflammatory cells as
compared to the saline or HKB groups. Instillation of BLES/budesonide resulted in
significantly lower numbers of inflammatory cells compared to HKB and budesonide
groups. Differential cell analysis showed that the administration of HKB resulted in a

162
significantly higher number of neutrophils compared to saline, but that both budesonide
and BLES/budesonide had significantly lower neutrophil counts compared to HKB
(Figure 4.2A). Additionally, the number of neutrophils was significantly lower in animals
administered BLES/budesonide compared to those given budesonide alone. The
instillation of HKB or HKB followed by budesonide also resulted in significantly higher
MPO activity compared to saline (Figure 4.2B). However, only animals instilled with
BLES/budesonide had significantly lower MPO activity compared HKB or budesonide
groups. The instillation of HKB or HKB followed by budesonide was also shown to result
in significantly higher levels of all pro-inflammatory cytokines tested compared to the
saline group (Figure 4.3A-D). Compared to animals administered HKB, those receiving a
second instillation of BLES/budesonide showed significantly lower IL-6 and TNF-α
concentrations (Figure 4.3A-B). Furthermore, the BLES/budesonide group showed
significantly lower concentrations of TNF-α and GRO/KC than the budesonide group
(Figure 4.3B-C). Although the BLES/budesonide group showed lower levels of MIP-2
and GRO/KC relative to HKB and budesonide groups, the levels were still significantly
higher than the saline group (Figure 4.3C-D).
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Figure 4.1. The effect of instilling budesonide or BLES/budesonide on the number of
inflammatory cells in BAL for pediatric rats. Solid circles indicate female rats, open
circles represent male rats. n = 10-17, *p<0.05 vs saline, +p<0.05.
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Figure 4.2. The effect of instilling budesonide or BLES/budesonide on the A) number of
neutrophils in the BAL and B) MPO activity in the lung tissue of pediatric rats. Solid
circles indicate female rats, open circles represent male rats. n = 10-17, *p<0.05 vs saline,
+

p<0.05.
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Figure 4.3. The effect of instilling budesonide or BLES/budesonide on pro-inflammatory cytokine concentrations in the BAL:
A) IL-6, B) TNF-α, C) GRO/KC, and D) MIP-2. Solid circles indicate female rats, open circles represent male rats. n = 9-12,
*p<0.05 vs saline, +p<0.05.
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Figure 4.4. The effect of instilling BLES on A) the number of inflammatory cells, and B)
the number of neutrophils in BAL, as well as C) MPO activity in the lung tissue of
pediatric rats. Solid circles indicate female rats, open circles represent male rats. n = 3.
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4.4 Discussion
This chapter tested the hypothesis that fortifying an exogenous surfactant
preparation, BLES, with budesonide would enhance efficacy for treating pulmonary
inflammation in vivo. Overall, our results supported this hypothesis. Specifically, BLES
was shown to enhance the anti-inflammatory effects of budesonide in a rat model of lung
inflammation by reducing the number of neutrophils, as well as the concentrations of a
several pro-inflammatory mediators in the BAL. Furthermore, combining budesonide
with BLES was shown to be beneficial for reducing MPO activity in the lung tissue. It
should also be noted that these results were displayed across both sexes. Based on these
observations, it is concluded that utilizing exogenous surfactant as a pulmonary vehicle
for budesonide enhanced its ability to treat lung inflammation.
To address our hypothesis, we utilized an in vivo model, where HKB was instilled
into the lungs of young rats. The rationale for using young rats was practical in nature to
limit animal usage, as these animals were also utilized for a separate experiment [19]. The
HKB solution contains a mixture of bacterial components, including lipopolysaccharides,
that caused a rapid inflammatory response as evidenced by the significant increases in
neutrophil counts, MPO activity and inflammatory cytokine concentrations as compared
to animals not receiving HKB. The experimental treatment tested was BLES/budesonide,
for which intratracheal instillation was confirmed via the increased surfactant levels in the
BAL fluid following the experiment. It should be noted that our experimental design did
not include a BLES only treatment. However, an additional experiment with 6 pups
revealed that BLES alone did not impact the inflammatory response induced by the
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instillation of HKB (Figure 4.4). Based on these considerations, we deem the
experimental approach an appropriate test of our hypothesis.
An important aspect of this chapter was the evaluation of a potential
glucocorticoid-based treatment strategy in both males and females. Although our
objective was not to understand the underlying pathways leading to potential sex
differences, numerous studies have demonstrated the role of sex in patient sensitivity to
glucocorticoid treatment [20–24]. Unfortunately, these previous studies have also been
inconsistent with respect to their findings. For example, when developing guides to
predict responsiveness among asthmatic children, both Wu et al. (2017) and Galant et al.
(2014) found that the female sex was associated with a higher likelihood of
responsiveness to inhaled glucocorticoids [20, 21]. On the contrary, some clinical trials
and epidemiological studies have observed beneficial effects for daily glucocorticoid
treatment in males, but not females [22, 23]. For the current model of pulmonary
inflammation, the instillation of HKB was found to result in similar inflammatory
responses among males and females. Moreover, no sex differences were found for the
responsiveness of rats to either of the glucocorticoid treatments. Since sex hormones have
been shown to play such an essential role in inflammatory responses, this lack of
differences may be related to the young, sexually immature, age of the animals [25].
Despite these findings, the extensive role sex hormones play in modulating inflammatory
pathways combined with the variability shown in human studies suggests that sex must be
considered when evaluating new glucocorticoid based treatment strategies [26].
From a clinical standpoint, this chapter builds on previous work in the neonatal
population. Specifically, it adds to previous clinical studies that explored exogenous
surfactant or glucocorticoids as preventative treatments for poor pulmonary outcomes and
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respiratory conditions like BPD [27, 28]. For example, there are a number of clinical
trials which have found that administering surfactant multiple times or using it as a
vehicle for budesonide may reduce the risk of BPD [29, 30]. Similarly, there have been
clinical trials that have found intratracheal instillations of budesonide, with a surfactant
vehicle helped to prevent the development of chronic lung disease among preterm infants
[31]. The current chapter expands these prophylactic approaches in premature lungs, by
demonstrating anti-inflammatory effects of this treatment strategy, subsequent to the
pulmonary inflammation.
To extrapolate our data to the clinical arena, there are a variety of respiratory
conditions that may benefit from an anti-inflammatory exogenous surfactant; however, its
potential for treating ARDS is of particular interest. In the first half of 2020, ARDS became
a well-known syndrome as the critical pulmonary complication resulting from severe acute
respiratory syndrome coronavirus-2 infections, known as COVID-19. However, even
before the emergence of COVID-19, ARDS was the most common cause of death in the
ICU, with no effective pharmacological therapies available [32–35]. Importantly, it has
been shown that disease severity and progression are directly associated with the
accumulation of neutrophils into the alveolar space [36, 37], and that many aspects of the
ARDS pathophysiology, such as edema formation and surfactant dysfunction, are
consequences of excessive inflammation in the lung [3]. This has provided a strong
rationale for glucocorticoid-based treatments, as evidenced by numerous clinical trials for
ARDS and the ongoing trial for COVID-19 [38–40]. Unfortunately, to date, these highly
effective anti-inflammatory medications have failed to prevent ARDS or show mortality
benefits [39, 40]. One interpretation of this data is that the efficacy of the glucocorticoids
is limited by suboptimal drug delivery. Based on our data, it is tempting to speculate that
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exogenous surfactant, as a delivery vehicle, will allow glucocorticoids to become an
effective treatment option for ARDS.
It should be noted that there are several limitations to this chapter. First, the
experiments within this chapter only explored the benefits of one surfactantglucocorticoid preparation. The improvements observed for budesonide when
administered with BLES, suggest therapeutic value in exploring a similar approach for
other glucocorticoids or anti-inflammatory medications. To this end, our lab intends to
perform more elaborate in vivo studies with multiple commercially available
glucocorticoids, like dexamethasone and hydrocortisone, to further explore the benefits of
surfactant delivery. Secondly, our model of pulmonary inflammation did not imitate the
edema or airway collapse observed in many respiratory conditions. The current chapter
did measure protein content in the BAL, however its unchanging level across treatment
groups suggests that a stronger stimulus is required to disrupt the alveolar-capillary
barrier. Although there is strong scientific evidence that exogenous surfactant can
overcome regions of edema and airway collapse, future studies should still evaluate this
treatment strategy under these inhibitory conditions [41].
In conclusion, this chapter demonstrates that the use of exogenous surfactant as a
delivery vehicle for budesonide can make it more effective for treating lung
inflammation. Further, we propose that this novel treatment strategy can overcome the
delivery challenges associated with respiratory conditions like ARDS and treat the
neutrophilic inflammation underlying the disease. With no effective pharmacological
options currently available for this condition, direct delivery with exogenous surfactant
offers an intriguing method for mainstay medications to begin effectively treating this
devastating disease.
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5.1 General Overview
The objective of this thesis was to develop a process through which exogenous
surfactants could be designed into more effective vehicles for intrapulmonary
therapeutics. The challenge of direct drug delivery to the alveoli and adverse
consequences of the current systemic dosing paradigm in respiratory conditions were the
rationale for pursuing this novel delivery strategy [1–7]. The hypothesis of this thesis was
that exogenous surfactant delivery would enhance the efficacy of antimicrobial
cathelicidins and anti-inflammatory glucocorticoids for the treatment of bacterial
pneumonia and ARDS, respectively. The specific pursuit of cathelicidins for surfactantbased delivery was brought on by the high incidence of bacterial pneumonia worldwide,
rising rates of AMR infections, and lack of new antimicrobials in development [3, 8–16].
Similarly, the investigation of glucocorticoid-surfactant mixtures was prompted by the
long clinical history of effectively treating lung inflammation with glucocorticoids and
the desperate need for new therapeutics to treat ARDS [17–23]. This final section will
summarize the major findings of each chapter. It will also explore their overall
significance to highlight how the chapter fits into the development process for exogenous
surfactants as drug vehicles, outlined throughout this thesis (Figure 5.1). Lastly, based on
the literature, and some additional limitations to those discussed in the chapters
themselves, this final section will propose future experiments to expand on the findings of
this thesis.
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Figure 5.1. Schematic summary of the surfactant-based drug development process
explored throughout this thesis.

5.2 Summary of Major Findings Chapter 2: The Wet Bridge
Transfer System
Chapter 2 began with the development and characterization of the wet bridge
transfer system as a model system for screening surfactant-based therapeutics. Briefly,
this in vitro platform utilized two connected wells, in which drugs were instilled into a
delivery well and function was tested in a remote well, allowing the system to mimic the
remote areas of the lung where drug activity would be required. The concept behind this
methodology was that surfactant injected into the delivery well would adsorb to the
surface and, through its spreading capabilities, transfer over the wet bridge to the remote
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well. The results of this chapter demonstrated that surfactant spreading across the wet
bridge was dependent on surfactant concentration and temperature, but independent of
administration volume. The technique was also utilized for screening therapeutics mixed
with surfactant, specifically antibiotics, by measuring their ability to kill P. aeruginosa
bacteria in the remote well, as well as anti-inflammatory agents, using stimulated
macrophages in the remote well and IL-6 concentration as an outcome. The basic idea
was that a drug combined with surfactant would be detected in the remote dish only if it
was transported by surfactant. Through these experiments, it was observed that the
potential efficacy of two antibiotics (gentamicin and ciprofloxacin) as well as two antiinflammatory agents (budesonide and CATH-2) benefited from surfactant delivery,
showing increased efficacy in the remote well compared to the drug alone. Based on these
findings, it was speculated that exogenous surfactant would be a useful pulmonary drug
delivery vehicle to improve the distribution of these medications in the lung. In contrast,
the antibiotic, colistin was not found to benefit from surfactant delivery as it was
concluded that the inhibitory effects of surfactant on colistin would limit the usefulness of
this antibiotic. Alternatively, the utilization of this antibiotic with surfactant would
require further optimization. Together, these findings showcased the wet bridge transfer
system as a versatile screening tool for surfactant-drug preparations.
Figure 5.2 shows how these findings fit into the overall experimental paradigm of this
thesis. Specifically, Chapter 2 highlighted the utility of the wet bridge transfer system as a
novel in vitro tool for rapidly screening surfactant-based therapeutics, prior to animal
studies. The technique expanded on currently available in vitro technology, including
methods for evaluating surfactant biophysics, to allow surfactant-drug mixtures to be
assessed based on their ability to maintain both 1) surfactant function (through its ability

181
to spread) and 2) therapeutic function (antibacterial or anti-inflammatory properties) at a
distal site (Figure 5.2). Thus, this relatively inexpensive in vitro screening tool would
have the potential to select optimal preparations to test in vivo and therefore reduce the
number of animal experiments required.
Beyond the limitations already discussed in Chapter 2, this chapter could be further
enhanced by a more rigorous biophysical analysis of surfactant-drug mixtures.
Specifically, other techniques, in addition to the wet bridge, could be utilized to assess the
effect of a drug on the surface tension lowering properties of an exogenous surfactant
during expansion/compression cycling [24–26]. For example, future experiments could
utilize the constrained sessile drop surfactometer (CDS) to further evaluate the effects of
a drug on surfactant function and design better synthetic surfactants. Through this
approach, researchers could put the retention of all aspects of surfactant function at the
forefront of the optimization process.
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Figure 5.2. Schematic summary highlighting how the new methodology of Chapter 2 (the
wet bridge transfer system) fits into the surfactant-based drug development explored
throughout this thesis.

5.3 Summary of Major Findings Chapter 3: Surfactant
Optimization
Figure 5.3 demonstrates how this data fits into the overall experimental paradigm
of this thesis. Specifically, the chapter utilized the wet bridge transfer system, in
combination with other in vitro techniques, to further explore the interactions between
cathelicidins and exogenous surfactant. The experiments in this chapter expanded upon a
previous study from our research group, which found that suspending cathelicidins in
BLES significantly impaired their antibacterial function [3]. The authors speculated that
the negatively charged PG component of surfactant was inhibiting the function of these
positively charged peptides. Thus, the goals of Chapter 3 were to determine if PG was an
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inhibitory agent within exogenous surfactant and subsequently design a functional, PGfree synthetic surfactant to increase peptide mediated killing of bacteria at a distal site.
Although many of the experiments described in Chapter 3 were also performed
with three additional cathelicidins (LL-37, CRAMP, PMAP-23), optimization was
concentrated on CATH-2, the cathelicidin previously shown to best retain its
antimicrobial properties when mixed with BLES [3, 14]. To better understand how
surfactant lipids interacted with CATH-2 and affected its bactericidal function, isothermal
titration calorimetry and solid-state nuclear magnetic resonance spectroscopy, as well as
bacterial killing curves against P. aeruginosa were utilized. The wet bridge transfer
system was also used to evaluate surfactant spreading and peptide transport (Figure 5.3).
Investigation of the interactions between individual surfactant lipids and CATH-2
revealed that PG was the only surfactant lipid to significantly inhibit CATH-2 function,
showing a stronger electrostatic interaction with the peptide than other lipids.
Furthermore, when the PG content of an existing surfactant was diluted, through the
addition of other surfactant lipids, the suspended CATH-2 displayed improved
antibacterial function. Based on these findings, it was theorized that the electrostatic
interaction between the negatively charged PG and positively charged peptide was likely
preventing CATH-2 from binding negatively charged lipids, DNA, or other bacterial
components. Lastly, although diluting the PG content in an existing surfactant, through
the addition of other lipids, significantly improved peptide function and distal killing, it
also reduced surfactant spreading. It was speculated that this loss of surfactant function
was caused by a dilution of not only PG, but other surfactant components, including SP-B
and SP-C. To overcome this impairment in surfactant spreading, synthetic mimics for SPB and SP-C were utilized, to develop a synthetic PG-free surfactant. Mixing this
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optimized synthetic surfactant with CATH-2 further improved its delivery and function at
a remote site. Based on these in vitro experiments, synthetic PG-free surfactants were
deemed optimal for delivering cathelicidins to the lung.

Figure 5.3. Schematic summary highlighting how the wet bridge transfer system and new
optimization approach of Chapter 3 (synthetic surfactants) fit into the surfactant-based
drug development explored throughout this thesis.

The findings within this chapter highlighted two important aspects. First, the
chapter demonstrated of how synthetic surfactants could be designed to retain both
surfactant and antimicrobial peptide function. Specifically, it showcased how the lipid
composition of synthetic surfactants could be optimized to overcome their electrostatic
interactions with CATH-2. As such, the chapter provided proof that synthetic surfactants
could be customized to deliver a specific therapeutic. Second, the chapter illustrated a
more mechanistic approach to developing surfactant-based drug vehicles through the use
synthetic surfactants and various in vitro techniques. Importantly, this approach could
potentially to be expanded to other therapeutics, improving suspended drug functionality,
while maintaining the spreading capabilities of surfactant.
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Within the chapter itself, several valid limitations were discussed. However,
Chapter 3 could have also benefited from a further expansion of its optimization process.
For example, with the proper insight into the structural characteristics of functional and
non-functional cathelicidins, the chapter could have benefited from the investigation of
designer peptides as part of its optimization of surfactant-peptide mixtures [27]. This
approach would integrate the optimization of the therapeutic, in addition to the surfactant
vehicle, into the optimization process outlined in this chapter. Further, although Chapter 3
thoroughly investigated the antibacterial properties of surfactant-cathelicidin mixtures, it
did not directly evaluate the effects of this interaction on the anti-inflammatory properties
of these peptides. There have been numerous studies demonstrating the potential of
cathelicidins as anti-inflammatory agents [28, 29]. Within our own lab, we have shown
the in vivo efficacy of a cathelicidin-surfactant mixture for reducing lung inflammation
[14]. However, the direct in vitro analysis of their anti-inflammatory properties alone and
in combination with an exogenous surfactant has been notably absent in the literature.
Thus, for cathelicidins delivered by a surfactant vehicle to become viable treatment
options for pneumonia, it would be recommended that future studies gain a better insight
into the effect of exogenous surfactants on their immunomodulatory properties.

5.4 Summary of Major Findings Chapter 4: Relevant Animal
Model
To expand on the in vitro findings of Chapter 2, this chapter explored the utility of
a surfactant vehicle for budesonide in vivo. Figure 5.3 demonstrates how utilizing a
relevant animal model of pulmonary inflammation fits into the overall experimental
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paradigm of this thesis. Specifically, an animal model of pulmonary inflammation was
created, through an intratracheal instillation of heat-killed P. aeruginosa into the lungs of
male and female rats. This inflammation was then treated thirty minutes later using a
second intratracheal instillation of either saline, budesonide, or BLES combined with
budesonide. The therapeutic efficacy of budesonide compared to surfactant delivered
budesonide was determined by measuring various markers of inflammation in the BAL
and lung tissue. Although budesonide exhibited anti-inflammatory effects when
administered alone for downregulating the number of neutrophils in the BAL, delivery
with BLES significantly enhanced those effects. Moreover, the BLES/budesonide
combination was found to significantly lower several other pro-inflammatory mediators
in the BAL and lung tissue compared to the drug alone. With these results being shown
across both sexes, it was concluded that utilizing exogenous surfactant to deliver
budesonide made it more effective for treating lung inflammation.
Chapter 4 has several significant findings as well as limitations. However, its
overall significance was its assessment of this surfactant-glucocorticoid mixture in a
relevant animal model (Figure 5.4). Specifically, it demonstrated that this antiinflammatory surfactant, administered after an inflammatory insult, was more effective
for reducing neutrophil-driven lung inflammation than the drug alone for both male and
female animals. These in vivo findings have clinical significance, as they further support
this therapy as a potential treatment for inflammatory conditions, notably ARDS. Based
on the chapter’s findings, it is tempting to suggest that a surfactant vehicle would allow
glucocorticoids to overcome the delivery challenges associated with ARDS and treat the
underlying neutrophilic inflammation. However, the clinical relevance of this animal
model to ARDS is a major limitation of Chapter 4. For example, as mentioned in the
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chapter itself, this rat model of lung inflammation did not imitate the edema or airway
collapse observed in ARDS patients. Further, this model and its outcomes did not fulfill
the criteria outlined by the American Thoracic Society guidelines for ARDS animal
models [30]. Notably, the guidelines recommend achieving at least three of the following
four criteria: 1) evidence of physiological dysfunction, 2) histological evidence of tissue
injury, 3) alteration of the alveolar capillary barrier, and 4) the presence of an
inflammatory response [30]. Thus, despite the supportive findings in this chapter, truly
understanding the therapeutic potential of a surfactant delivered glucocorticoid for
ARDS, would require a more clinically relevant animal model of the disease.
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Figure 5.4. Schematic summary highlighting how the in vivo assessment of
BLES/budesonide in Chapter 4 (relevant animal model) fits into the surfactant-based drug
development explored throughout this thesis.

5.6 Future Directions: Cathelicidins
As mentioned above, most of the research surrounding cathelicidins, as well as
their combination with exogenous surfactants has focused on their ability to kill AMR
bacteria. However, their ability to regulate the immune system could also be beneficial
for treating bacterial pneumonia. Unfortunately, it is unknown if exogenous surfactant
inhibits the immunomodulatory properties of these peptides. Specifically, their ability to
electrostatically bind negatively charged microbial by-products could be a potential
mechanism inhibited by a surfactant vehicle. The wet bridge experiments within Chapter
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2 established an in vitro model for evaluating the anti-inflammatory properties of
therapeutics, including a cathelicidin. As such, this model could be easily modified to
directly assess the anti-inflammatory properties of different cathelicidins alone or in
combination with an exogenous surfactant. Based on the findings of these initial wet
bridge experiments, as well as the extent of surfactant’s inhibitory effects, the next logical
step would be optimization. The approach would be similar to Chapter 3, investigating
the effect of different lipid components on the anti-inflammatory function of different
cathelicidins, with the ultimate goal of developing a more ideal synthetic surfactant.
Lastly, optimal surfactant-cathelicidin combinations should also be explored in vivo.
Specifically, in a relevant animal model for pneumonia with outcomes for both their
antimicrobial and anti-inflammatory effects.
The goal of the wet bridge experiments should be to screen different cathelicidins
in combination with a surfactant vehicle. However, the in vitro model could also be
expanded. For example, the wet bridge experiments could utilize primary or alveolar
macrophages isolated from animals or even ARDS patients. Further, a more diverse range
of inflammatory outcomes could be measured with additional techniques. For example,
cells and media could be collected for measuring NF-κB activation, as well as the level of
other inflammatory cytokines (TNF-α, IL-1β, and IL-8) by qPCR and ELISA. To gain a
better functional measurement of the inflammatory response, media could also be
collected for a neutrophil chemotaxis assays, an approach that would require a
chemotaxis chamber. By expanding outcomes to include a greater variety of proinflammatory mediators, these experiments will further the current understanding of the
immunomodulatory properties of cathelicidins in combination with exogenous surfactant.
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5.5 Future Directions: Glucocorticoids In Vitro
As mentioned previously, the biophysical analysis of synthetic surfactants in
combination with various therapeutics could be expanded beyond the wet bridge transfer
system. Notably, glucocorticoids, one of which was explored in vitro in Chapter 2 and in
vivo in Chapter 4, have been shown to negatively impact the surface tension lowering
properties of exogenous surfactants during expansion/compression cycling [31–33]. Thus,
through the use of additional techniques that can assess surfactant function during
expansion/compression cycling, the optimization process established in Chapter 3 could
be expanded to create ideal synthetic surfactants for glucocorticoids.
A common interpretation of the inhibitory effects of glucocorticoids on surfactant
function is that they are associated with the structural similarity between glucocorticoids
and cholesterol [31–34]. Briefly, at normal levels within pulmonary surfactant,
cholesterol associates with DPPC containing domains and has minimal impact on
surfactant function (Figure 5.5). In contrast, elevated cholesterol, beyond levels that will
only interact with DPPC, will begin to alter the non-DPPC containing domains [35, 36].
This creates a more fluid structure, which has been shown to impair surfactant function.
Therefore, developing a functional cholesterol-free synthetic surfactant, with a high
DPPC concentration would be ideal for delivering glucocorticoids like budesonide. The
basic idea being to create synthetic surfactants less susceptible to inhibition by the
glucocorticoids and/or have the capacity to carry larger amounts of the glucocorticoid to
remote sites.
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Figure 5.5. A schematic comparison of surfactant films with A) no cholesterol, B) normal
amounts of cholesterol, and C) high amounts of cholesterol. Elevated cholesterol leads to
surface film collapse and surfactant dysfunction.

To assess this concept experimentally, techniques like the CDS could be utilized
in addition to the wet bridge transfer system to evaluate surfactant function [37]. Like the
optimization process for cathelicidins (Chapter 3), researchers could develop synthetic
surfactant mixtures using individual surfactant lipids and protein mimics, creating varying
concentrations of cholesterol and DPPC. These surfactant mixtures would then be
evaluated on the wet bridge system for spreading and the CDS for their function during
expansion/compression. Once functional synthetic surfactants were established, these
biophysical techniques could then be utilized to determine the concentration dependent
inhibitory effects of various glucocorticoids compared to cholesterol. Additionally, the
anti-inflammatory effects of these glucocorticoids, delivered by cholesterol-free synthetic
surfactants, could be evaluated on the wet bridge, utilizing a stimulated macrophage
model (Chapter 2; see section 5.6 Future Directions: Cathelicidins). Lastly, to further
explore glucocorticoid-surfactant mixtures as a therapy for ARDS, it would be
recommended that the specific glucocorticoids, dexamethasone, methylprednisolone, and
hydrocortisone, be investigated, in addition to budesonide. These glucocorticoids are all
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commercially available and have been previously utilized in clinical trials or animal study
for ARDS (Table 1.3) [38, 39]. Thus, their optimization with a synthetic surfactant
vehicle could result in a new arsenal of anti-inflammatory medications for ARDS to be
tested in animal studies.

5.7 Future Direction: Glucocorticoid In Vivo
Assessing the therapeutic efficacy of glucocorticoids delivered by exogenous
surfactants for ARDS, requires a clinically relevant animal model. ARDS is a complex
and heterogenous disease. However, a sepsis-induced rat model, which incorporates
mechanical ventilation would represent the clinical scenario and could expand upon the
findings of Chapter 4.
Experimentally, male and female rats could be given an intraperitoneal injection
of fecal slurry solution or undergo cecal ligation and puncture surgery to induce sepsis
[40–42]. Then rats would be connected to a rodent ventilator, with the mechanical
ventilation settings being based on protective low tidal volume guidelines currently used
in the clinical setting [18]. For treatments, rats on the mechanical ventilator would receive
an intratracheal bolus of either 1) saline, 2) glucocorticoid, 3) exogenous surfactant, or 4)
surfactant-glucocorticoid. As stated earlier, the American Thoracic Society guidelines
recommends at least three of the following four criteria for an ARDS model: 1) evidence
of physiological dysfunction, 2) histological evidence of tissue injury, 3) alteration of the
alveolar capillary barrier, and 4) the presence of an inflammatory response [30].
Therefore, the outcomes of this experiment should be based on completing these criteria.
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To determine evidence of physiological dysfunction, it would be suggested that
various physiologic outcomes be monitored during ventilation, including lung compliance
and peak inspiratory rate. In addition, mean arterial pressure, heart rate and baseline blood
gas measurements, such as arterial oxygenation could also be assessed. Like the in vivo
experiment performed in Chapter 4, the inflammatory response within the lung could be
evaluated by performing a BAL and freezing lung tissue. The BAL could be analyzed to
calculate inflammatory cell counts and differentials, as well as the concentrations of
various pro-inflammatory cytokines. The lung tissue could be homogenized for an MPO
activity assay. However, these inflammatory outcomes could also be expanded by
investigating with qPCR, macrophage polarization, or immunocytochemistry. For
example, in an additional cohort of animals, lung tissue could be collected and fixed for
immunohistochemical analysis of cellular influx (e.g. stain for Ly6B.2 to determine
interstitial neutrophil infiltration). For assessing alterations to the alveolar-capillary
barrier, a wet/dry ratio of the lung could be determined, in addition to the BAL being
analyzed to determine protein levels. Vascular permeability could also be examined by
measuring Evan’s blue albumin leak into the pulmonary tissue. For histological evidence
of tissue injury, it would be recommended that fixed lung tissue be sectioned and scored
by a pulmonary pathologist blinded to experimental groups. In addition, although not part
of the recommended guidelines, we would suggest evaluating alterations in endogenous
pulmonary surfactant function and pool size, perhaps through the utilization of the CDS,
as well as a phosphorous assay. Lastly, there are multiple reasons for the recommendation
of rats instead of mice for this model: 1) it would be easier to collect larger quantities of
samples, 2) many labs, including our own lab have more experience ventilating rats, and
3) rats show greater physiological stability when placed on a ventilator than mice do [43,
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44]. Together, these factors, as well as the discussed outcomes should allow this rat
model to fulfill the American Thoracic Society guidelines and assess this novel therapy in
a clinically relevant ARDS model.

5.8 Concluding Remarks
Based on the data accumulated throughout this thesis, we conclude that exogenous
surfactants can be utilized to enhance the distribution and therefore efficacy of
intrapulmonary therapeutics. Its utility as a carrier for pulmonary therapeutics makes
intuitive sense and, more importantly, is supported by scientific evidence. Chapter 2
showcased the newly developed wet bridge transfer system and how it could be utilized to
study surfactant as a drug carrier, as well as screen surfactant-based therapeutics (Figure
5.2). Chapter 3 demonstrated how customized synthetic surfactant could extend the
delivery benefits of a surfactant vehicle to compounds previously shown to have their
therapeutic function impaired by exogenous surfactants (Figure 5.3). Further, this chapter
demonstrated how a more thorough understanding into the interactions of drug-surfactant
preparations, could result in synthetic surfactants specifically designed to retain a drug’s
function and surfactant function. Chapter 4 showed how relevant animal models could be
utilized to expand upon the currently available in vitro tools for studying surfactant as a
drug carrier and assess their in vivo efficacy (Figure 5.4). Together, these chapters
outlined a process for surfactant design that integrated both in vitro and in vivo studies,
enhanced the understanding of surfactant as a drug carrier, and allowed for continuous
feedback to improve on previous experiments (Figure 5.1). It is the opinion of this author,
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that this integrative approach will be essential to translate the basic idea of surfactant as a
carrier for pulmonary drugs toward clinical trials and ultimately clinical practise.
To illustrate the concepts associated with surfactant-based drug delivery the
experiments within this thesis focused on bactericidal compounds (cathelicidins) for
pneumonia and anti-inflammatory agents (glucocorticoids) for ARDS. However, the
potential drug targets for these conditions are not limited to antimicrobial and antiinflammatory agents. For example, a β2 agonist to reduce edema formation associated
with ARDS has been investigated [45, 46]. Unfortunately, meta-analysis of the data did
not show a benefit of the drug and, in fact, indicated the potential of detrimental effects
[47]. Although other conclusions are feasible, inadequate drug delivery to the target site
may have contributed to these undesirable results. Specifically related to the β2 agonist,
delivery of this drug via aerosol will unlikely reach the edematous areas of the lung where
the drug is required. Revisiting this drug, and concept of reducing edema in ARDS, by
studying its combination with surfactant has the potential for different outcomes. This
concept may apply not just to β2 agonists, but also to the many other pharmacological
agents that have been unsuccessfully tried in patients with pneumonia or ARDS [19, 48,
49]. Additionally, whereas this thesis primarily focused on bacterial pneumonia and
ARDS as potential clinical targets, it should also be noted that other pulmonary diseases
may be equally appropriate for the utilization of surfactant-based therapies. For example,
drugs for pulmonary fibrosis or emphysema, marked by a thickening and destruction of
the alveolar walls respectively, may be potential targets for such investigations. Further,
one can also imagine delivery of other components, for example contrast agents for
various imaging approaches, to the lung via surfactant-based administration. As such, we
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are certain that surfactant as a vehicle for various drugs and other compounds is a
promising approach in a variety of circumstances requiring pulmonary delivery.
Lastly, this thesis provided strong in vitro and in vivo data supporting the more
targeted use of cathelicidin- and glucocorticoid-fortified surfactants in patients afflicted
with bacterial pneumonia or ARDS. For cathelicidin-fortified surfactants, the
combination is clearly a bit behind in its development towards clinical trials compared to
glucocorticoids. However, based on the strong scientific data presented throughout this
thesis, they clearly have potential and should be explored in relevant animal models. For
glucocorticoids, the data from our thesis implies that that the combinatorial effect of
exogenous surfactant with these drugs may overcome the limitations of those observed
for each therapy, in previous clinical trials [50–57]. As such, the next logical step for the
developmental process presented in this thesis would be to assess the combination in
large animal models and design phase 1 or 2 clinical trials. The assessment of this
therapeutic combination in clinical trial is also supported by the ongoing trials of
surfactant therapy to treat COVID-19 patients and surfactant-glucocorticoid combination
in infants [58–62]. Simply put, the glucocorticoid-surfactant approach is a repurposing of
two clinically approved drugs that are currently utilized in humans [63, 64]. Thus, the
initiation of such trials should be relatively straightforward.
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